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SUMMARY 
 
Azathioprine (AZA) is one of the most widely used immunosuppressant drugs for the 
treatment of many inflammatory diseases, in particular autoimmune diseases where it is 
often administered as a steroid-sparing drug. It blocks T- and B-cell proliferation through 
incorporation of its active metabolites, 6-thioguanine nucleotides, into DNA. AZA is 
mainly catabolised through the thiopurine S-methyltransferase (TPMT) and xanthine 
oxidase (XO) pathways. While 70% of patients respond to AZA, 30% do not respond or 
show intolerance to the drug. Variants of genes coding for TPMT or XO, or other gene 
members of either pathway, which result or not in mutated enzymes, are believed to 
influence individual responses to AZA. With the aim of uncovering possible genotype-
phenotype correlations that would help personalize AZA treatment through response-
specific SNP profiles, we have analyzed TPMT and XDH (the gene coding for XO) for 
SNPs in 71 Italian patients in the context of their response to AZA (intolerant patients, n = 
25; unresponsive patients, n = 16; and responsive patients, n = 30). We confirm the 
presence of known intronic and exonic TPMT and XDH polymorphisms not correlating 
with particular AZA responses. We identified two new intronic polymorphisms, G420-4A 
in TPMT and T652-21A in XDH, each in one intolerant patient. Whether or not intolerance 
is related to these mutations in the patients must be further elucidated. In XDH, we 
detected two novel non-synonymous mutations (c.G1004A, p.Arg335His; c.C2891T, 
p.Thr964Ile), one new synonymous mutation (c.G1194A, p.Leu398Leu), and one novel 
non-synonymous polymorphism (c.C1167T, p.Ala556Val). The missense mutation, 
p.Arg335His, is likely to have an effect on the structural conformation of the FAD-binding 
domain, thereby destabilizing the protein structure. This could therefore lead to a 
decreased XO activity, for example through increased protein degradation or through 
deficient binding of FAD, hence reduced efficiency of the enzyme function, and thereby 
intolerance to AZA as observed. The other non-synonymous mutation, p.Thr964Ile, 
occurred in the molybdopterin domain; it was found in one responsive patient, suggesting 
that this mutation did not modify the structure of the domain sufficiently to affect the 
enzymatic activity. The non-synonymous polymorphism, p.Ala556Val, causes a change 
from Ala to Val at position 556 in the connection segment between the FAD-binding and 
molybdopterin domains, which is unlikely to have a significant effect on the protein. This 
XDH polymorphism was found in one intolerant, one unresponsive, two responsive 
patients, and 3/100 healthy controls; it is therefore unlikely to be of significance in 
43 
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pharmacogenetic profiles predictive of AZA responses. The silent mutation, p.Leu398Leu, 
identified in an intolerant patient should not cause functional impairment of XO. 
Linkage disequilibrium (LD) of TPMT SNPs and haplotype analysis thereof demonstrated 
a new haplotype designated TPMT*3E; it comprises the previously reported mutations of 
the TPMT*3A allele associated with intolerance to AZA and the intronic T140+114A SNP. 
TPMT*3E was detected in four of the 25 AZA-intolerant patients and was not observed in 
unresponsive or responsive patients. The association of TPMT*3E with AZA intolerance, 
and its frequency, must be ascertained in larger, ethnically different cohorts. Nevertheless, 
in view of the highly significant association (Psim = 0.037) between TPMT*3E and AZA 
intolerance in our study, this haplotype should be taken into account when considering 
AZA treatment.  
LD analysis of XDH identified four different haplotype blocks, one of which was 
significantly associated with intolerance in our cohort (Psim = 0.017). This block includes 
five SNPs, one intronic and four located in the 3' untranslated regions (3' UTRs); these 
were previously described as single SNPs, but were not analyzed in the context of response 
to AZA. It is unclear how this haplotype results in intolerance to AZA. One possibility is 
that the SNPs affect the regulation of protein expression through alteration of the target 
sites for microRNAs that interact with the 3' UTRs to regulate the expression of mRNAs. 
This could therefore lead to AZA intolerance in our patients, through in an increase in 
down-regulation of XDH mRNA and thereby XO expression. In this work, we have 
demonstrated new haplotypes that should be taken into consideration in pharmacogenetic 
profiling for AZA. In particular, SNPs in the XDH have been poorly investigated thus far 
in the context of response to AZA; the new XDH haplotype is of major interest in the 
establishment of pharmacogenetic profiles that will permit prediction of the type of 
response to AZA, in particular to prevent life-threatening side effects. It should be further 
studied in the context of its association with other response-defining haplotypes or SNPs of 
TPMT and other AZA metabolism pathway genes.  
II 
INTRODUCTION 
 
1. AZATHIOPRINE 
 
1.1. History 
 
Azathioprine (AZA) was synthesised in 1957 by Elion and Hitchings.1 Azathioprine is 
among the oldest pharmacologic immunosuppressive agents in use today. Initially 
developed as a long-lived prodrug of 6-mercaptopurine (6-MP), it was quickly found to 
have a more favourable therapeutic index.2 Initially evaluated for the treatment of 
leukaemia in the 1950s, AZA was introduced in the 1960s as immunosuppressant for organ 
transplantation. The use of thiopurine has also been reported for inflammatory bowel 
disease, such as Crohn’s disease and ulcerative colitis,3 haematological malignancies, 
rheumatologic diseases,2 and autoimmune diseases.4-6 
AZA (Figure 1a) and 6-MP (Figure 1b) have been used in the clinic for more than five 
decades. Inhibition of purine nucleotide biosynthesis and eventually suppression of DNA 
and RNA synthesis, and down-regulation of B and T cell proliferation have been suggested 
as major therapeutic mechanisms.7 The immunosuppressive action of AZA is delayed, 
starting 3-6 months after treatment is initiated.4 
 
a.    b.  
Figure 1. Chemical structure of (a) azathioprine and (b) 6-mercaptopurine 
 
1.2. Mechanism of action 
 
Azathioprine is a prodrug, a pharmacologically inactive chemical derivative that can be 
used to transiently alter the physicochemical properties of drugs, to increase their 
usefulness and/or to decrease associated toxicity. Generally, prodrugs can be converted in 
1 
vivo, enzymatically or non-enzymatically, into active drug molecules to exert a therapeutic 
effect.8 
After oral administration and absorption, approximately 90% of the prodrug AZA 
undergoes conversion to 6-MP, the pharmacological molecule, by non-enzymatic binding 
of sulphydryl-containing compounds such as glutathione (GSH) or cysteine that are present 
in every mammalian cell.7 As shown by other studies, another mode of biotransformation 
of AZA involves enzymatic conjugation with GSH to form 6-MP, catalyzed by glutathione 
S-transferase (GST). GST consumes GSH, which is normally present in abundance in 
hepatocytes9 (Figure 2). 
AZA is believed to act through the insertion into DNA and RNA of its metabolic products, 
thioguanine nucleotides (TGNs). These are produced through the metabolic pathway which 
converts 6-MP to 6-thioinosine 5’-monophosphate (TIMP), TIMP to thioxanthine 
monophosphate (TXMP), and TXMP to thioguanosine monophosphate (TGMP), through 
the action of hypoxanthine-guanine phosphoribosyl transferase (HGPRT), inosine 
monophosphate synthetase (IMPDH), and guanosine monophosphate synthetase (GMPS), 
respectively (Figure 2). TGMP is then metabolised to form di- and tri-phosphate TGNs. 
Thiopurine S-methyltransferase (TPMT), aldehyde oxidase (AO), and xanthine oxidase 
(XO) compete with HGPRT, which initiates the metabolism of 6-MP to TGNs, for the 
initial metabolism of 6-MP. TPMT can act not only on 6-MP, but also on two 
intermediates of the HGPRT pathway, TIMP and TGMP. As substrates for TPMT, 6-MP 
and TGMP form methylmercaptopurine (MeMP) and methyl thioguanosine 
monophosphate (MeTGMP), respectively,10 whereas TIMP is converted to S-methyl-
thioinosine 5’-monophosphate (MeTIMP), a strong inhibitor of de novo purine synthesis 
believed to contribute significantly to the cytotoxic action of 6-MP. 
2 
 Figure 2. Metabolism of AZA. The various steps leading to the formation of thioguanine 
nucleotides (TGNs) are catalyzed by glutathione S-transferase (GST), hypoxanthine guanine 
phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH), guanosine 
monophosphate synthase (GMPs). The oxidation is catalyzed by xanthine oxidase (XO) and 
aldehyde oxidase (AO); the methylation is carried out by thiopurine methyltransferase (TPMT) 
using the methyl donor S-adenosyl-L-methionine (SAM). The compounds produced in the various 
metabolic steps are: 8-hydroxythioguanine (8-OHTG); methyl-mercaptopurine (MeMP); 
thioinosine-monophosphate (TIMP); methyl-thioinosine-monophosphate (MeTIMP); thioxanthine-
monophosphate (TXMP); thioguanine-monophosphate (TGMP) and methyl- thioguanine-
monophosphate (MeTGMP). 
 
The TGN metabolites of 6-MP act as purine antagonists and inhibit DNA, RNA, and 
thereby protein synthesis, inducing cytotoxicity and immunosuppression. More recently, 
AZA was also shown to interfere at the protein level itself. Tiede et al. showed that in vitro 
stimulation of primary human T lymphocytes in the presence of AZA or 6-MP results in an 
increased percentage of apoptotic cells.7 6-MP was shown to induce apoptosis by 
converting the CD28-mediated co-stimulatory signalling implicated in T-cell activation 
into an apoptotic signal, through direct interaction of its 6-thioguanine triphosphate 
metabolite with Rac1, a small GTPase whose activation upon CD28 costimulation appears 
to control pathways known to prevent T-cell apoptosis. Binding of 6-thioguanine 
triphosphate to Rac1 apparently suppresses the activation of Rac1 target genes leading to a 
mitochondrial pathway of apoptosis.7 
 
1.3. Side effects 
 
Adverse effects may occur in 15 to 30% of patients treated with AZA. These side effects 
can be divided into two groups: one consists of non–dose related effects such as 
pancreatitis, fever, malaise, rash, nausea, diarrhoea and hepatitis; the second consists of 
dose-related effect, such as leucopoenia, thrombocytopenia, infection, malignancy and 
GST HGPRT IMPDH GMPSAZA 6-MP TIMP TXMP TGMP TGNs
AO XO
8-OHTG
TPMT
SAM
MeMP
Thiouric acid
TPMT
SAM
MeTIMP
TPMT
SAM
MeTGMP
3 
hepatitis.11 Thomsen et al. showed that during AZA therapy 5/439 children with acute 
lymphoblastic leukaemia developed secondary myelodysplasia or acute myeloid 
leukaemia.12 More recently, three case reports have described new side effects of AZA. In 
the first case report, de Boer described a 35-year-old man who presented with hepatitis, 
nodular regenerative hyperplasia, veno-occlusive disease, fibrosis and sinusoidal dilatation 
upon treatment with AZA. Hepatitis is considered to be an idiosyncratic reaction to AZA, 
the other side effects are considered to be signs of dose-dependent hepatotoxicity.13 The 
second case showed recurrent atrial fibrillation in a patient with ulcerative colitis treated 
with AZA. Atrial fibrillation can be a serious but reversible adverse effect.14 The third case 
report showed that immunosuppressive drugs such as corticosteroids or AZA could induce 
hepatitis B virus reactivation in patients carrying hepatitis B virus surface antigen, albeit 
much less frequently than chemotherapy treatments.15 
 
2. THE MAJOR PATHWAYS FOR AZA METABOLISM. INFLUENCE OF 
GENETIC VARIATIONS IN RESPONSE TO THE DRUG 
 
AZA and 6-MP undergo extensive first-pass metabolism, and the contribution of the three 
major metabolic pathways (TPMT, XO and HGPRT) to individual variations in its 
metabolism has been studied by pharmacogenetics.16 
 
2.1. Thiopurine S-methyltransferase 
 
Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that catalyzes the S-
methylation of aromatic and heterocyclic sulfhydryl compounds, including cytotoxic and 
immunosuppressive thiopurine medications such as mercaptopurine, azathioprine and 
thioguanine.17 While TPMT is an important determinant of toxicity with these medications, 
no endogenous substrate is known for this enzyme and its biological role remains 
obscure.18 
The TPMT gene is located on chromosome 6 (6p22) and consists of 10 exons and 9 introns 
(Figure 3). It encodes a 245 amino acid protein with a predicted molecular mass of 35 
kDa. A processed pseudo gene of TPMT has also been described with 96% homology to 
the TPMT gene; it is located on chromosome 18q21.1.10 
The 5’ promoter region has a 71% GC content; it has no consensus sequences for TATA 
box or CCAAT elements, and contains several binding sites for well-characterized 
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transcription factors including Sp1, NF-k, AP-2 and KROX-24.18 Variable number tandem 
repeats have been identified in the 5’UTR.19 
TPMT enzymatic activity is inherited as an autosomal codominant trait. In humans, it is 
controlled by a genetic polymorphism at the TPMT locus and approximately 1 in 300 
individuals has very low TPMT activity, 11% have intermediate activity, and 89% show 
normal/high activity.20 Several clinical studies found that high methylators may be under-
treated with conventional doses of thiopurine drugs, whereas intermediate and deficient 
methylators are recognized to be at risk of moderate to profound haematopoietic toxicity 
when treated with standard doses of the medications. These observations are explained by 
an inverse relationship between TPMT activity and the production of TGNs.21 
 
 
 
 
 
Figure 3. Gene structure of thiopurine S-methyltransferase (TPMT). Solid white boxes, coding 
exonic sequence. Solid grey boxes, non-coding exonic sequence. Sizes of the exons, but not the 
introns, are shown proportional to their real lengths. 
 
2.2 TPMT allelic mutations 
 
Many rare genetic variants exist in the human population, but most of the heterozygosity in 
the population is attributable to common alleles, that is those that are present in the general 
population at a frequency of >1% (single nucleotide polymorphisms). Single nucleotide 
polymorphisms (SNPs) can occur in the coding sequence or in the intronic region. If they 
are in the coding sequence, they could or could not determine an amino acid change in the 
protein sequence. If they are in the intronic sequence, they could modify mRNA splicing, 
causing the synthesis of a mutated protein. 
Currently, a total of 35 different TPMT allelic variants have been characterized. They may 
be associated with a decreased TPMT activity and/or induced toxicity. Inactive TPMT 
alleles contain mutation(s) in the open reading frame (ORF), resulting in the synthesis of a 
protein that is more rapidly degradable, or in intron-exon junction, leading to an altered 
mRNA splicing. Some SNPs in TPMT gene cause a structural disruption and misfolding of 
the clinically important drug-metabolizing enzyme. Misfolded proteins can be removed 
5’ 3’
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from the cell by degradation, but they can also form aggregates. Aggregosome formation 
represents a unique process by which cells can remove misfolded TPMT protein.22 
The “wild type” TPMT allele, which determines high enzyme activity, is defined as 
TPMT*1. The mutant alleles can be divided in four groups: TPMT alleles associated with 
normal activity; TPMT alleles suspected to decrease enzyme activity; inactive TPMT 
alleles and intronic TPMT alleles. 
The first group includes those polymorphisms which do not cause alteration in the TPMT 
enzymatic function. Two silent polymorphisms (no amino acid change) were identified in 
the fifth (c.C339T, p.Thr113Thr) and the seventh (c.C474T, p.Ile158Ile) exons; both 
alleles are termed TPMT*1S.23 Other polymorphisms (C-178T, T-30A, G-23T) were 
detected in the 5’UTR region in exon 1, a non-coding region of the TPMT gene. c.C-178T 
is indicated as TPMT*1A; the other two have not been named24,25 (Figure 4). 
 
 
 
 
Figure 4. TPMT alleles associated with normal activity. Hatched boxes, exons containing at least 
one mutation; white boxes, exons with normal sequence. Solid gray boxes, non-coding exonic 
sequence. Sizes of the exons, but not the introns, are shown proportional to their real lengths. 
 
The second group includes the alleles which present non-synonymous mutations resulting 
in amino acid change and are suspected to decrease TPMT activity, even if a clear and 
indisputable association is still lacking. These mutations are extremely rare. TPMT*7 and 
TPMT*10 are characterized by a non-synonymous mutation in exon 10 (c.T681G, 
p.His227Glu) and in exon 7 (c.G430C, p.Gly144Arg), respectively. They were identified 
in patients treated with conventional doses of AZA who developed severe leucopenia. In 
vitro experiments showed that the TPMT*7 and TPMT*10 allelic variants are a loss-of-
function, but the molecular/structural basis for the detrimental influence of the amino acid 
change on TPMT activity remains to be elucidated.26 TPMT*8, which contains a single 
nucleotide transition (c.G644A) leading to an amino acid change at codon 215 
(p.Arg215His), was found in an Afro-American cohort of patients with intermediate 
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activity. This mutation was not found in any other Afro-American individuals and the 
mechanism by which it is associated with low TPMT activity is still unclear.27 Schaeffeler 
et al. found TPMT*9 (c.A356C, p.Lys119Thr) in two individuals, one with an intermediate 
activity and the other with a normal TPMT activity, so this polymorphism does not seem to 
be associated with low TPMT activity. TPMT*17 (c. C124G, p.Gln42Glu) and TPMT*18 
(c.G211A, p.Gly71Arg) were each described in only one patient. They seem to be 
associated with decreased TPMT activity leading to an intermediate TPMT phenotype.28 
These mutations were not found in other individuals tested and the mechanism by which 
they are associated with low TPMT activity is unknown. Hamdan-Khalil et al. during a 
routine genotyping of patients with Crohn’s disease identified one non-synonymous 
mutation, TPMT*19 (c.A365C, p.Lys122Thr), in a Caucasian patient who had an apparent 
normal TPMT activity.21 TPMT*20 consists of a mutation in exon 3 (c.G106A, 
p.Gly36Ser), with a frequency of 0.003 in the Japanese population. The Gly36Ser 
substitution is closely located to the methyl donor S-adenosylmethionine binding site of the 
N-terminal end of TPMT. Thus, the mutation is expected to alter the catalytic properties of 
TPMT, but this has yet to be demonstrated.29 TPMT*20* (so called thereafter to 
distinguish it from TPMT*20 previously identified in the Japanese population) and 
TPMT*22 consist in an amino acid change in exon 10 (c.A712G, p.Lys238Glu) and in 
exon 7 (c.G488C, p.Arg163Pro), respectively.30 TPMT*20* and TPMT*22 alleles appear 
to be extremely rare in the Caucasian population, and TPMT*20* is associated with 
intermediate activity, albeit at levels close to normal activity.30 TPMT*23 is a rare 
polymorphism which consists in a substitution in exon 8 (c.C500G) that determines an 
amino acid change (p.Ala167Gly). Alignment of human TPMT and orthologs indicated 
that Ala is highly conserved at this position, and the substitution of Ala for Gly at position 
167 was predicted to be deleterious, resulting in defective enzyme function.31 TPMT*24 is 
a rare non-synonymous mutation located in exon 8 c.T634C that results in p.Gln179His 
substitution. The definite functional status of TPMT*24 remains difficult to ascertain and 
further in vitro analyses are needed to demonstrate its impact on TPMT expression and/or 
stability32 (Figure 5). 
7 
  
Figure 5. TPMT alleles suspected to decrease activity. Hatched boxes, exons containing at least 
one mutation; white boxes, exons with normal sequence. Solid gray boxes, non-coding exonic 
sequence. Sizes of the exons, but not the introns, are shown proportional to their real lengths. 
 
The third group includes polymorphisms of TPMT gene which cause an amino acid change 
responsible for the inactivity of the protein. TPMT*3A, TPMT*3B TPMT*3C and TPMT*2 
are the most prevalent mutant alleles in Caucasians, Asians, and Afro-Americans, 
comprising approximately 95% of TPMT mutant alleles in these populations. TPMT*2 
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contains a single nucleotide change in exon 5 (c.G238C, p.Ala80Pro), TPMT*3B includes 
a single mutation in exon 7 (c.G460A, p.Ala154Thr), TPMT*3C contains a single mutation 
in exon 10 (c.A719G, p.Tyr240Cys) and TPMT*3A contains two mutations, one in exon 7 
(c.G460A, p.Ala154Thr) and the other in exon 10 (c.A719G, p.Tyr240Cys). Each of these 
mutant alleles has been shown to cause TPMT deficiency. TPMT*3A is the most prevalent 
mutant allele in Caucasians, whereas TPMT*3C is the predominant TPMT mutant allele in 
Asian, African, and Afro-American populations.33,34 
TPMT*2, assessed in a yeast heterologous expression system, led to a 100-fold reduction 
in TPMT catalytic activity compared to the wild-type, despite a comparable level of 
mRNA expression.35 TPMT*3A is rapidly degraded by an ubiquitin-proteasome mediated 
process, with the involvement of molecular chaperones.36 This observation is in 
accordance with a growing body of evidence demonstrating that an alteration in protein 
level is a common mechanism underlying the functional effects of genetic polymorphisms 
involving non synonymous SNPs, most often as a result of accelerated protein 
degradation.37 In contrast, TPMT*5 (c.T146C, p.Leu49Ser) might alter the enzymatic 
function of the protein.34 
TPMT*3D is a haplotype which consists in the TPMT*3A mutations plus another 
polymorphism at nucleotide 292 (c.G292T) in exon 5, which replaces the codon for Glu98 
by a frame-stop codon (p.Glu98X). It determines intermediate enzyme activity. TPMT*4 
has a G-1A transition at the intron 9/exon 10 splice junction that modifies the final 
nucleotide of the intron at the invariant 3’-acceptor splice site sequence required for RNA 
processing. TPMT*6 is characterized by a substitution A>T at nucleotide 539 (c.A539T) in 
exon 8 resulting in a p.Tyr180Phe substitution. This allele was identified in a Korean 
subject and caused low TPMT activity.38 Schaeffeler et al. identified a mutation, c.G395A, 
in exon 6, that results in p.Cys132Tyr, which defines allele TPMT*11; the molecular 
mechanism for loss of catalytic activity has not been elucidated. However, similarly to 
TPMT*2 and *3A, a post-transcriptional mechanism with enhanced proteolysis of the 
mutant protein seems to be the most likely explanation.39 TPMT*12 (c.C374T, 
p.Ser125Leu) results in enzyme with significantly reduced intrinsic clearance values, about 
3.5-fold lower than wild-type TPMT. Based on in vitro data, Hamdan-Khalil et al. 
postulated that TPMT*12 and another demonstrated allele, TPMT*13 (c.A83T, 
p.Glu28Val), correspond to loss-of-function alleles of TPMT.26 TPMT*14 is defined by a 
mutation in the first nucleotide of the coding sequence (c.A1G, p.Met1Val). According to 
the NCBI ORF finder, the theoretical consequence of TPMT*14 may be a truncated 
9 
protein: use of a downstream ATG as a start codon will result in a shortened protein of 170 
amino acids compared to the wild-type 245 amino acid-long TPMT. Allele TPMT*15 has a 
G-1A transition at the intron 7/exon 8 splice junction of the TPMT gene. One possible 
consequence is the deletion of the entire exon 8 in the final protein, resulting in a frame 
shift and a premature stop codon in exon 9 that would lead to a truncated 173 amino acid-
long protein.40 Hamdan-Khalil21 genotyped two Crohn’s disease patients by TPMT cDNA 
sequencing, revealing the presence of one non-synonymous mutation in exon 7 
corresponding to c.G488A, p.Arg163His substitution (TPMT*16). TPMT*16 can be 
considered a very rare TPMT variant with a frequency <0.1%. This allele encodes a protein 
with a severely impaired catalytic efficiency and could then be considered as a non-
functional allele in the context of phenotype prediction via genotyping tests.21 TPMT*21 
consists in a mutation in exon 4 (c.C205G, p.Leu69Val) and leads to a substantial decrease 
in TPMT activity in vivo.30 The TPMT*25 (c.T634C, p.Cys212Arg) allele is not expected 
to occur frequently in Caucasian populations. The Cys212Arg mutation is located on the 
protein surface away from the catalytic site. This solvent-exposed mutation is characterized 
by a modification in ionic charge that could destabilize the local electrostatic balance in the 
native protein, likely resulting in a protein with a significantly reduced catalytic activity 
toward 6-TG methylation compared to the wild-type enzyme, as observed through 
structural analysis. Consequently, this allelic variant can be regarded as belonging to the 
non-functional alleles of TPMT.32 In the last years, three other mutations were found to be 
associated with low TPMT activity: c.T622C, p.Phe208Leu in exon 9 (TPMT*26); 
c.T319G, p.Tyr107Asp in exon 5 (TPMT*27); c.T611C, p.Ile204Thr in exon 9 
(TPMT*28)41-43 (Figure 6). 
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Figure 6. Defective TPMT alleles. Hatched boxes, exons containing at least one mutation; white 
boxes, exons with normal sequence. Solid gray boxes, non-coding exonic sequence. Sizes of the 
exons, but not the introns, are shown proportional to their real lengths. 
 
Intronic polymorphisms were detected at nucleotide T140+114A and A141-101T in intron 
3, and at nucleotide T366+58C in intron 5 (Figure 7). These polymorphisms do not cause 
TPMT*28
T611C 
(Ile204Thr) 
TPMT*27
T319G
(Tyr107Asp) 
TPMT*26
T622C 
(Phe208Leu) 
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alteration in TPMT activity. However, definitive linkage analysis and the impact on 
enzyme activity must await characterization of a larger number of samples.38,23 
 
 
Figure 7. Intronic polymorphisms. Hatched boxes, exons containing at least one mutation; white 
boxes, exons with normal sequence. Solid gray boxes, non-coding exonic sequence. Sizes of the 
exons, but not the introns, are shown proportional to their real lengths. 
 
2.3 Activity of TPMT 
 
Neither the biological role of TPMT nor its endogenous substrate have been defined as yet, 
but we know that TPMT-deficient patients are at risk of severe and potentially fatal 
hematopoietic toxicity, unless their thiopurine dosage is decreased by 10-15 fold.44,45 In 
addition to genetic polymorphisms, tissue-specific differences in TPMT gene expression 
have been documented, with the highest level in liver and kidney and relatively low levels 
in brain and lung. TPMT expression may also exhibit developmental regulation, as 
erythrocyte activity is higher (about 50%) in newborns than in healthy adults, resulting in a 
higher TPMT protein content in erythrocytes of newborns.46 Erythrocyte TPMT activity is 
approximately 30% higher when children with leukaemia are taking mercaptopurine, and 
returns to pre-treatment levels when thiopurine therapy is stopped.18 
 
2.4 Limitations in analysis of TPMT activity 
 
Individuals who have inherited a mutated TPMT gene can develop a hematopoietic toxicity 
when treated with standard doses of 6-MP or AZA. The determination of TPMT activity in 
red blood cells could therefore be a predictive test for intolerance before starting with a 
thiopurine therapy. However, analysis of TPMT activity currently shows limits. Indeed, in 
particular cases, TPMT activity can not be determined correctly: when a patient 
heterozygous for TPMT SNPs has received blood transfusions from a wild-type individual 
(the test must then be made 60 days after blood transfusion); when the patient takes AZA 
already, because the presence of AZA induces a natural increase of TPMT activity by 
approximately 20% above the basal value; or when the patient takes other drugs such as 
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sulfasalazine or olsalazine, that are strong inhibitors of TPMT.28 There is therefore a need 
for approaches to predict TPMT activity, and thereby drug response to AZA, that 
overcome the limitations of enzyme activity testing. 
 
3. XANTHINE OXIDASE 
 
Xanthine oxidase (XO) is a cytoplasmatic enzyme that catalyzes the last two steps of 
purine degradation: oxidation of hypoxanthine to xanthine and xanthine to uric acid with 
concomitant reduction of NAD+ (dehydrogenase) or molecular oxygen (oxidase). XO 
oxidizes purines, pyridines, pterins, and aldehydes, and it is also involved in the 
metabolism of clinically significant drugs such as 6-MP, allopurinol (an XO inhibitor), 
pyrazinamide (an antituberculous agent),47 and azathioprine. XO metabolizes 
approximately the 10% molar equivalent of a normal daily AZA dose, and it is excreted as 
urinary 6-tiouric acid (6TU).48 
Xanthine oxidoreductase enzymes have been isolated from a wide range of organisms, 
from bacteria to man. All of these proteins have similar molecular weights and 
composition of redox centres.49 XO and xanthine dehydrogenase (XDH) are both members 
of the molybdenum hydroxylase flavoprotein family and represent different forms of the 
same gene product. The two enzyme forms and their reactions are often referred to as 
xanthine oxidoreductase activity. XDH is a homodimer with a subunit molecular mass of 
approximately 150 kDa. Conversion of XDH into XO is a two-step process with the initial 
step involving the oxidation of the important protein thiol groups. Irreversible cleavage of 
a 20 kDa fragment from each of the subunit by a calcium-dependent protease subsequently 
converts XDH into XO.50 The active form of the enzyme is a homodimer of 290 kDa 
molecular mass, with each of the monomers acting independently in catalysis. Each 
subunit contains one molybdopterin domain, two spectroscopically distinct [2Fe-2S] 
centres, and one FAD cofactor. The oxidation of xanthine takes place at the molybdopterin 
centre (Mo-pt) and the electrons thus introduced are rapidly distributed to the other centres 
by intramolecular electron transfer (Figure 8).49 The highest XO activities are found in 
human liver and bowel as opposed to other tissues. High levels of XO have been associated 
with tissue injury in certain diseases and is considered to contribute to oxidative damage of 
cells through the generation of cytotoxic oxygen radicals, which are implicated as 
important pathological mediators in many clinical disorders, including ischemia-
reperfusion injury, myocardial infarction, hypertension, and atherosclerosis.51,52 
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Figure 8. 3D structure of xanthine oxidase. 
 
There is inter-individual variation in human liver XO activity, and about 20% of Caucasian 
subjects display relatively lower enzyme activity.53 Hence, about 11% of Japanese54 and 
4% of Spanish individuals55 are likely to be poor metabolizers of XO substrates and XO 
deficiency occurs in 2% of the general French population.56 
XDH polymorphisms have been well characterized among Caucasians and Asians but not 
in Africans.57 The human XDH gene has been mapped to chromosome 2p22. The XDH 
gene spans over 60000 bp of DNA and can be divided into 36 relatively small exons. Exon 
36 is over 700 bp long and contains the last few translated amino acids and the entire 3’-
untranslated region. Each of the remaining 35 exons consists of 50-280 bp. The 5’ flanking 
region is characterized by a sequence similar to that of an initiation site, lacking the 
canonical TATA boxes and several binding sites for various transcription factors. This 
region appears to be that of a highly regulated TATA-less gene and this is consistent with 
its tissue specific expression and modulation by various stimuli at the transcriptional 
level.50 The XDH gene encodes approximately 1330 amino acids and each monomer of 
XDH can be divided into three domains. The small N-terminal domain (residues 1 to 165, 
20 kDa) contains both iron/sulphur cofactors and is connected to the second, FAD-binding, 
domain (residues 226 to 531, 40 kDa) by a long segment consisting of residues 166 to 225. 
The FAD domain is connected to the third domain by another linker segment (residues 532 
to 589). The large third domain, residues 590 to 1335 (85 kDa), sequesters the Mo-pterin 
cofactor close to the interfaces of the Fe/S- and FAD-binding domains. The C-terminal 
domain spans residues 1310 to 133549 (Figure 9). 
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Figure 9. Scheme of XDH monomer and subdivision in functional domain. Exons are shown as 
black boxes. Note that the depiction of the XDH gene is not to scale. 
 
The amino acids mainly involved in the active site in the iron-sulphur domain are cysteines 
implicated in disulphide bounds: Cys 43, Cys48, Cys51, Cys73, Cys113, Cys116, Cys148, 
Cys150; those implicated in the active site of the FAD binding domain are: Phe337, 
Asp360, Leu404, Lys422; and the amino acids involved in the active site of the 
molybdopterin domain are: Gln768, Phe799, Glu803, Arg881, Arg913, Phe915, Thr1011, 
Ala1080, Glu1262 (proton acceptor).58 
 
3.1. XDH single nucleotide polymorphisms 
 
Many mutations and SNPs are known to occur in the XDH gene. In 1997, Ichida et al. 
identified the first two XDH mutations in Japanese patients affected by xanthinuria. These 
two mutations determine deficiency in XO activity. One subject had a C to T base 
substitution at nucleotide 682 (c.C682T) that caused a CGA (Arg) to TGA (STOP) 
nonsense substitution at codon 228 (p.Arg228X). The duodenal mucosa from the subject 
had no xanthine dehydrogenase protein, despite normal mRNA levels. The other subject 
had a C deletion at nucleotide 2567 that generated a modified protein with a termination 
codon 72 amino acids after the mutation.59 In 2000, Levartovsky et al. found in an Iranian-
Jewish family a 1658insC insertion in exon 16 of the XDH gene, which causes a translation 
frame shift predicting a truncated protein of 569 amino acids with an altered C-terminal 
amino acid sequence. The predicted truncated protein is thought to be functionally 
compromised, since amino acid residues needed for the formation of the putative NAD 
N-terminal domain
Fe/S cofactor
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Connection 
segment 
(166-225)
FAD binding 
domain
(226-531)
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segment 
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binding domain (encoded by exon 22), the molybdopterin binding site (encoded by exons 
22 and 23) and the amino acid residues involved in the conversion of XDH to XO (exons 
16, 27, and 36) are lost.60 In 2001, Sakamoto et al. demonstrated a point mutation of C to T 
in nucleotide 445, which changes codon 149 from CGC (Arg) to TGC (Cys) (c.C445T, 
p.Arg149Cys), in one patient. The substitution of arginine by cysteine was identified near 
the cysteine residue that is proposed to participate in the iron-sulphur centre. Therefore, 
this substitution may change the tertiary structure of XO, leading to an absence of XO 
activity.61 In 2003, Gok et al. identified a new mutation in exon 20, an A to T base change 
at nucleotide position 2164 (c.A2164T) indicating a non-synonymous substitution from 
AAG (Lys) to TAG (Tyr) at codon 722 (p.Lys722Tyr). The consequences on protein 
activity of this new mutation are unknown.62 
Two large studies were conducted in 2008. Yang et al. genotyped the XDH gene of 48 
subjects affected by hypertension. They identified three non-synonymous mutations 
(c.G514A, p.Gly172Arg; c.G2794A, p.Ala932Thr; c.A3326C, p.Asn1109Thr) and five 
synonymous variations (c.G627A, p.Glu209Glu; c.C837T, p.Val279Val; c.C2211T, 
p.Ile737Ile; c.T3030C, p.Phe1010Phe; c.G3717A, p.Glu1239Glu). Whether or not these 
mutations cause a modification in XO enzyme activity remains to be ascertained.63 Kudo et 
al. genotyped the XDH gene of 96 unrelated Japanese volunteers. They found 19 non-
synonymous and 3 synonymous mutations. They also studied the functional activity of XO 
in mutant subjects. The results showed a deficiency in enzyme activity in two variants 
(c.C445T, p.Arg149Cys and c.C2729A, p.Thr910Lys); low activity in six variants 
(c.C1663T, p.Pro555Ser; c.G1820A, p.Arg607Gln; c.C1868T, p.Thr623Ile; c.C2727A, 
p.Asn909Lys; c.C3449G, p.Pro1150Arg and c.G3953A, p.Cys1318Tyr); and hyper-
activity in two variants (c.A2107G, p.Ile703Val and c.A3662G, p.His1221Arg).47 Finally, 
in 2010, Jureca et al. found, in a patient affected by rheumatoid arthritis, a new deletion in 
exon 8 (c.641delC, p.Pro214QfsX4) resulting in a frame-shift change, with a change of 
proline into glutamine at residue 214. The reading frame stops four codons after the 
mutation and the resulting mutated protein has only 218 amino acids. This protein has the 
first small N-terminal domain (residue 3–164 amino acids), which contains the Fe-S 
cofactors, and an incomplete second, FAD-binding, domain (192–527 amino acids).64 
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4. PHARMACOGENETICS, PHARMACOGENOMICS AND 
PERSONALIZED MEDICINE 
 
Adverse drug reaction in patients causes more than 2 million hospitalizations including 
100000 deaths per year in the United States.65 This adverse drug reaction could be due to 
multiple factors such as disease determinants, environmental and genetic factors. In order 
to improve the efficacy and safety of drugs and understand their clinical consequences, two 
rapidly developing fields – pharmacogenetics (focused on one or a few genes) and 
pharmacogenomics (focused on drug metabolism pathways) – are helping in genetic 
personalization of drug response. Indeed, many drug responses appear to be genetically 
determined and the relationship between genotype and drug response may have a very 
valuable diagnostic value. Identification and characterization of a large number of genetic 
polymorphisms (biomarkers) in drug-metabolizing enzymes and drug transporters in an 
ethnically diverse group of individuals may provide substantial knowledge about the 
mechanisms of inter-individual differences in drug response. Although individualized 
medications remain a challenge for the future, the pharmacogenetic approach to understand 
drug response should be further developed in order to identify biomarkers at the genetic 
level and apply this knowledge, not only to improve public health, thereby avoiding 
adverse drug reactions (by knowing in advance who should be treated with what drug and 
how), but also towards drug development66 (Figure 10).  
 
 
 
Figure 10. Pharmacogenomics and pharmacogenetics aim to identify patients at risk for toxicity or 
reduced response to therapy prior to medication selection. 
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Many genes encoding proteins involved in the metabolism, transport, and mechanism of 
action of medications are known to exhibit polymorphism in humans, but the use of this 
knowledge in routine clinical practice is limited. In fact, even if a gene has a large effect on 
a drug’s pharmacokinetics or pharmacodynamics, the presence of a single-nucleotide 
polymorphism in that gene will not provide an unequivocal answer but, rather, will 
indicate the likelihood that an individual patient will show an altered drug response.67 
Recent pharmacogenetic studies have mainly focused on immunosuppressive agents 
including corticosteroids, AZA, metotrexate and infliximab.68 Variability in the expression 
of pharmacokinetic (PK) genes can either slow or accelerate the uptake, conversion, or 
excretion of drugs, which can result in compounds or their active metabolites being 
eliminated before achieving a therapeutic effect, or remaining too long or in too high 
concentration so that the risk of adverse events increases.69 An example of a gene encoding 
an enzyme involved in PK process is TPMT. TPMT catalyzes the S-methylation 
(inactivation) of the thiopurine drugs, mercaptopurine, AZA, and thioguanine. In 
hematopoietic tissue, TPMT is the predominant inactivation pathway, so patients who 
inherit TPMT deficiency accumulate excessive levels of active thioguanine nucleotides 
after receiving standard doses. Numerous studies have shown that TPMT-deficient patients 
are at high risk of severe, sometimes fatal, hematologic toxicity; TPMT heterozygotes have 
an intermediate risk of hematologic toxicity. Actually more than 98% concordance exists 
between TPMT genotype and phenotype, and genotyping is highly sensitive (90%) and 
specific (99%) in identifying patients who have inherited one or two non-functional TPMT 
alleles.67 
The impact of common polymorphisms in TPMT on clinical outcome with AZA treatment 
has become a classic example of the application of pharmacogenetics, and is one of the 
first development in this field to be widely adopted in clinical practice. The other gene that 
has been subjected to significant enquiry in the context of AZA treatment is XO. The 
bioavailability of 6-MP has been estimated as approximately 5-37% owing to the presence 
of large amounts of XO in the liver. This bioavailability increases when XO inhibitors such 
as metotrexate are administrated concomitantly with 6-MP. Competitive inhibition of XO 
with allopurinol pre-treatment results in 5-fold increase in the bioavailability of oral 6-MP. 
Concurrent use of allopurinol and 6-MP has been reported to cause severe myelotoxicity. 
6-MP-induced adverse effects may increase in poor XO metabolizer.70 Wong reported that 
the levels of active metabolites are undetectable when XO activity is strong, in fact in a 
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patient with high XO enzyme activity, 6-TGNs could not be detected despite AZA 
administration of 150 mg/die.71 
 
AIM OF THE STUDY 
 
Single nucleotide polymorphisms influence the response to thiopurine drugs. Many 
defective and potentially deficient alleles were identified for TPMT that cause intolerance 
to azathioprine. XDH gene also showed many different polymorphisms that determine 
defective or hyper-XO activity, which have not yet been tested for possible association 
with AZA intolerance or unresponsiveness. 
Currently, the pharmacogenetics knowledge does not fully to explain the unresponsiveness 
and the majority of intolerant patients to azathioprine, and there is a need to further define 
pharmacogenetic profiles that can guide pharmacological therapy. 
Since azathioprine is used in the treatment of different diseases, the aim of our study is to 
perform genotypic analysis of TPMT and XDH genes, involved in the catabolism of AZA, 
to identify those new polymorphisms and possibly novel haplotypes that could determine 
adverse response or unresponsiveness to azathioprine. 
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MATERIALS AND METHODS 
 
1. SUBJECTS 
 
DNA samples from a cohort of 71 Italian patients with autoimmune diseases treated with 
AZA were obtained from the DNA bank of the Neurology IV Unit at Neurological Institute 
Carlo Besta, Milan, Italy or extracted from peripheral blood. Written informed consent for 
DNA storage and use for research purposes was obtained from all patients, as required by 
the ethical committee of Foundation Neurological Institute “Carlo Besta”, which approved 
the study. The patients underwent AZA treatment and were grouped according to their 
response to the appropriate dose of AZA (2-3 mg/kg per day): responsive after at least one-
year follow-up if they achieved pharmacological remission, or if clinical course was stable 
and steroid dosage had been reduced to at least 50% of pre-AZA level; intolerant, if they 
experienced persistent side effects upon AZA treatment, such as described by Ansari et 
al.,72 which could only be abrogated by withdrawal of the drug; or unresponsive if they 
showed neither clinical improvement nor adverse effects after a one-year treatment73. 
Clinical data were obtained retrospectively from the records available at the Neurology IV 
Unit database and reviewed by a doctor blinded for the genotyping results. 
 
2. DNA EXTRACTION 
 
Genomic DNA was extracted according to standard procedures from fresh or frozen 
samples of whole peripheral blood from AZAtreated patients and healthy individuals and 
stored at -20°C pending assays. 
 
3. PCR AND DNA SEQUENCING 
 
The genomic structure and intron boundary sequences were derived from the NCBI’s 
RefSeq database, access numbers NG_012137.1 (genomic sequence) and CCDS4543.1 
(coding sequence) for TPMT gene and access numbers NG_008871.1 (genomic sequence) 
and CCDS1775.1 (coding sequence) for XDH gene. Primers specific for TPMT exons 3, 4, 
6, 8, and 9, and/or intronic sequences containing known polymorphisms38 were identified 
using the Primer Express software package (Applied Biosystem, Foster City, CA); primers 
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specific for exons 5, 7, and 10 of TPMT gene and XDH gene were previously reported.23,47 
PCR amplification was carried out in a total volume of 25 µl containing 200 ng of genomic 
DNA, 1x DyNAzyme Buffer (Finnzymes, Celbio, Rho, Italy), 0.2 mM each GeneAmp 
dNTP (Applied Biosystems), 0.04 U DynaZyme DNA I DNA Polymerase (Finnzymes), 
and 0.5 µM of the specific primer pair. PCR reactions were performed on a GeneAmp PCR 
System 2700 (Applied Biosystem). Thermal cycling conditions to amplify exons 5, 7, and 
10 of TPMT gene and all exons of XDH gene were according to Schaeffeler et al. and 
Kudo et al.23,47 For the other TPMT exons, thermal cycling conditions were as follows: 
94°C for 5 min, followed by 35 cycles of 30 s at 94°C, 30 s at 55°C, and 1 min at 72°C, 
followed by 7 min at 72°C. PCR products (10 µl) were analyzed on 2% ethidium bromide-
stained agarose gel electrophoresis, purified (2.5 µl of each) using ExoSAP-IT (GE 
Healthcare, Milan, Italy), and sequenced using Big Dye terminator v3.1 Cycle Sequencing 
Kit and a ABI 3100 Genetic Analyzer (Applied Biosystem). The sequences were analyzed 
using SeqScape v2.1.1 (all from Applied Biosystem). New nucleotidic changes identified 
were confirmed by at least two different PCR and sequencing reactions. The known TPMT 
polymorphisms that were analyzed in this study are listed in Table 1 and those of XDH 
gene in Table 2.  
The new nucleotidic changes that were detected in this study in our cohort of 71 patients 
were classified as mutations if they occurred with a frequency < 1% and not found in any 
of the control individuals; they were classified as polymorphisms if they occurred with a 
frequency >1%, including in control individuals. 
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Table 1. TPMT polymorphisms analyzed by DNA sequencing in this study 
 
Exon SNP (dbSNP identifier where available) a 
3 T-30Ab; G-23Tb; A1G (rs9333569); T30Cc; G42Ac (rs111674665); C70Tc (rs16880307); 
A83T (rs72552742); T97G (rs72552741); G106A; C124G 
4 T146C (rs72552740); C205G (rs79321208); C211G 
5 G238C (rs1800462); C244T (rs111901354); G292T (rs72552739); C339Tc (rs17839843); 
G340A (rs115106679); A356C; A365C 
6 C374T; G395A (rs72552738) 
7 A423Cc (rs16880276); A424C; G430C (rs72552737); G460A (rs1800460); C474Tc 
(rs2842934); C487T (rs112339338); G488C; G488A 
8 C500G (rs74423290); G537T (rs6921259); A539T (rs75543815); T547C (rs113525437) 
9 T611C (rs79901429); T622C (rs72556347) 
10 T634C; G644A (rs56161402); T646C (rs17849975); T681G (rs72552736); A712C; 
A719G (rs1142345) 
Intron  
3 T140+114A (rs3931660); A141-101T (rs12529220) 
5 T366+58C (rs2518463) 
7 G496-1A 
9 A627-1G 
awww.ncbi.nlm.nih.gov/snp; bPolymorphism located upstream of the start codon; cSilent 
polymorphism 
 
Table 2. XDH polymorphisms analyzed by DNA sequencing in this study 
 
Exon SNP (dbSNP identifier where available) a 
1 G7A (rs144150776);G18T (rs113323020) 
2 T78C (rs112608986)b; A98G(rs146551089) 
3 G104A (rs139321199); G135A (rs150847028)b; C178T (rs184424277); G192T 
(rs182317768) 
5 G328A (rs147286954); C339T (rs118042822)b; C385T (rs145064943); G397A 
(rs45447191); C405T (rs72549370)b; C426G (rs192763480)b 
6 C445T; G446A (rs148108999); C463A (rs145413551); C468T (rs146749952)b 
7 500delG (rs45462996); 501delT (rs143464813); T501G (rs143464813)b; G514A 
(rs45523133); C561G (rs191822672) 
8 T572A (rs1126469); G627A (rs45575032)b; T632A (rs147724051); T636C (rs140225517)b; 
641delC  
9 G671A (rs112466737); C682T; C697T (rs149487595); A704T (rs45469499);  C762T 
(rs140858800)b; G763A (rs151251011) 
10 G822A (rs113345553)b; T825C (rs145596057)b; A829G (rs149853739); G835A 
(rs150515123); C837T (rs4407290)b; C859G (rs138674014); T876A (rs149541044); C882T 
(rs138246330)b;G883A (rs142335345) 
11 C981T (rs147062442)b; C1037T (rs142388231) 
12 G1042A (rs192453952); C1101T (rs149225690)b; T1122A (rs1126470)b 
13 C1134T (rs45612738)b; C1170G (rs146169510); A1184T (rs34929837); C1199T 
(rs140879910); G1238T (rs148024324) 
14 C1274G (rs138649664); G1329A (rs45471294)b; G1357A (rs185036611) 
15 G1495A (rs150262349); C1509G (rs45612839)b; T1514C (rs140685462); G1523A 
(rs148603901); C1535G (rs74874345); G1554A (rs143879399)b; C1565A (rs139199704); 
G1581A (rs138859065)b; G1597A (rs147476468); C1602T (rs61731080)b 
16 G1617T (rs117399514)b; A1624G (rs149150797); C1629T (rs140651875)b; G1653A 
(rs80188867)b; 1658InsC; C1663T (rs45577338); G1677T (rs183162063) 
17 T1707G (rs144540305)b; G1724A (rs147195351); C1726T (rs139772558); G1749A 
22 3
(rs141831710)b; A1751C (rs45491693); C1773T (rs145108969); G1774A (rs141314828); 
C1785T (rs140066757)b; C1800T (rs139964785)b; G1801A (rs61731081); G1820A 
(rs45442092); G1851T (rs45442398) 
18 C1868T (rs45448694); G1885A (rs148464316); T1896G (rs14959399); C1911T 
(rs142197675)b; A1936G (rs17323225); C1970T (rs143481133) 
19 C2022T (rs185713366)b; A2037C (rs139998082)b; A2069G (rs181111808); C2084T 
(rs142001530) 
20 T2106A/G (rs72549368)b; A2107G (rs17011368); T2108A I (rs142848703); A2126G 
(rs146345594); T2159C (rs72552333); A2164T (rs72549367); G2176A (rs61731083) 
21 T2206A (rs141470276); 2206delT (rs141470276); T2210C (rs72549366); C2211T 
(rs2295475)b 
22 G2340T (rs150879057); G2347A (rs138717520); C2350T (rs141938849); C2359T 
(rs148904866); G2360A (rs149717617); A2362T (rs141050887); G2372A (rs143887178); 
C2413T (rs140007233); G2437C (rs142951412); C2441T (rs148585342); T2452C 
(rs139272198) 
23 C2460T (rs143539472); G2477A (rs150297607) 
24 2567DelC; G2581T (rs76810353); G2602C (rs148269820); C2626G (rs140982129) 
25 T2634C (rs146994573)b; A2660G (rs145291309); T2684A (rs139272445); C2727A 
(rs566362); C2729A (rs669884); C2729T (rs669884); C2772T (rs143471207)b; G2794A  
26 C2827T (rs144514609); G2828A (rs138396004); G2851A (rs142675390); T2858G 
(rs137975977); G2877A (rs151059034)b; G2911A (rs148921536) 
27 T3018C ( rs144883930)b; C3027T (rs72549365)b; T3030C (rs1884725)b  
28 C3084T (rs45604135)b; C3126T (rs141214032)b; A3133G (rs142402298) 
29 G3203A (rs186225688); A3205G (rs146283435); G3234A (rs111951522)b; C3249T 
(rs45562835)b; G3271C (rs45619033)  
30 A3326C (rs45547640); C3348T (rs150419940)b 
31 A3375G (rs45592238)b 
32 C3449G (rs1042036); T3488C (rs142988357) 
33 C3526T (rs45624433); C3530T (rs148972840); T3536C (rs139515054) 
34 C3647A (rs143981573); G3660A (rs146264603)b; A3662G; C3665T (rs148235835); 
C3667T (rs116290580); G3717A (rs207440)b; G3724A (rs183714440); C3736T 
(rs142329784); G3737A (rs140606023); C3738T (rs151338723)b; A3764T (rs147253350); 
G3771A (rs45594136)b 
35 C3792T (rs113929916)b; G3841A (rs181743036); T3864C (rs148477626)b; A3875G 
(rs73922346); C3886T (rs45564939); G3887A (rs139691722); G3909A (rs143920171)b; 
G3920A (rs138249576); C3930T (rs138936101); A3937G (rs141335716) 
36 G3953A (rs2295474)  
Intron  
2 C100+27T (rs206801) 
4 A307-33G (rs10175754) 
17 G1857-4A (rs17395175) 
20 G2197+42C (rs761926); G2197+68A (rs2281550) 
23 A2544+35T (rs2365842) 
25 G2824-35A (rs13419410) 
27 C3052-12G (rs13415401) 
30 A3352-30C (rs207454) 
34 C3774+32G (rs45591431) 
3’UTR A4002+518G (rs1042039); A4002+1477G (rs6710015); C4002+1516T (rs1054889); 
G4002+1555T (rs6752058) 
awww.ncbi.nlm.nih.gov/snp; bSilent polymorphism 
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4. SPLICE SITE PREDICTION  
 
Splice site of TPMT intron was predicted through BDGP: Splice Site Prediction by Neural 
Network (http://www.fruitfly.org/seq_tools/splice.html), which runs the NNSPLICE 0.9 
version of the splice site predictor. 
 
5. XDH NEW EXONIC MUTATION ANALYSIS 
 
To evaluate the effect of exonic mutations on protein structure and enzymatic activity, we 
calculated the protein stability (ddG) upon mutation(s) using FoldX forcefields 
algorithm.74 The default FoldX parameters were used (Temperature: 298 K; Ion strength: 
0.05 M; pH: 7; Van der Waals Design: 2): if the mutation destabilizes the structure, ddG is 
increased, whereas stabilizing mutations decrease the ddG. Since the FoldX error margin is 
around 0.5 kcal/mol, changes in this range are considered insignificant. The XO 
crystallography structure (pdbID: 2E1Q) 
[http://nist.rcsb.org/pdb/explore/explore.do?structureId=2E1Q] was used as template. First, 
the tertiary structure was energetically minimized using the “RepairPDB” function of 
foldX.75 
 
6. STATISTICAL ANALYSIS OF TPMT AND XDH GENES 
 
Hardy-Weinberg equilibrium (HWE, p-value >0.05) and minor allele frequency (MAF 
<1%) were tested for each locus. Calculation and visualization of pairwise linkage 
disequilibrium (LD) between SNPs were carried out using the software Haploview version 
4.1. Pairwise LD among the SNPs was assessed using standard coefficient D’ and LD 
coefficient expressed as r2.76 The degree of LD among SNPs to partition haplotype blocks 
was examined using the Solid Spine algorithm in Haploview v4.1. Haplotype-trait 
associations were tested within the 18 kb block region of TPMT and 71.5 kb block region 
of XDH that contain the SNPs defined for the respective genes. 
 
7. HAPLOTYPE ASSOCIATION ANALYSIS 
 
Haplotype frequencies were estimated by Expectation Maximization (EM) algorithm; the 
inferred haplotypes with frequencies greater than 0.01 were compared between responders 
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and intolerant patients to test associations statistically with Haplo.score package as 
outlined by Schaid et al.77 The computed global score and haplotype-specific p-values 
were calculated and adjusted sex as a clinical covariate under the additive model. The p-
values were corrected for multiple testing by 10000-time permutation tests. The 
relationships between haplotype and clinical outcome were examined using a generalized 
linear model regression of trait-on-haplotype effect (haplo.glm function), which estimates 
regression coefficients corresponding to each haplotype. 
25 
RESULTS 
 
1. PATIENTS’ RESPONSIVENESS TO AZA 
 
Of the 71 patients treated with azathioprine, 30 were classified as responsive to AZA, 16 as 
unresponsive,73 and 25 as intolerant72 with side effects including gastric intolerance (9/25 
patients), hepatotoxicity (11/25 patients), leucopenia (1/25 patients), rash (1/25 patients), 
myelosuppression (1/25 patients) and others (2/25 patients). A summary of patient data is 
shown in Table 3. Steroids were given in association with AZA to 54 patients (76%); in 
the remaining seventeen patients (10 intolerant, 3 unresponsive and 4 responsive to AZA), 
AZA was administered alone because steroids were contraindicated or not tolerated. 
 
Table 3. Patient data and responses to AZA 
 
Response to AZA Intolerant (n=25) Unresponsive (n=16) Responsive (n=30) 
Sex 19/6 14/2 19/11 
Age at the first AZA 
administration (years) 
43.7±15.1 
(19-67) 
46.7±18 
(24-81) 
50±20.9 
(15-85) 
 
2. NEW INTRONIC POLYMORPHISM G420-4A IN TPMT GENE 
 
Because our SNP identification strategy uses primers that, in addition to the relevant 
exonic sequence, allow the amplification of about 50 bases of intronic sequences flanking 
the exon on each side, in TPMT gene we found a previously undescribed nucleotidic 
change (G420-4A) located 4 bases upstream of exon 7 in one intolerant patient with a 
heterozygous genotype (Figure 11a). We submitted this SNP to NCBI SNPs database78 
and it has been assigned the RefSNP ID: rs56019966. We have sequenced the relevant 
DNA region from 100 randomly selected healthy individuals and detected this new SNP in 
only one individual (Figure 11b). Because of its position at the beginning of exon 7, the 
newly identified intronic polymorphism could affect the splicing process; however, 
prediction of the splice sites for exon 7 indicates that a mutation from G to A would not 
change the acceptor site or result in a new acceptor site for splicing of exon 6 to exon 7 
(Figure 11c). 
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a.  b.  
 
c.
… atttgatttttctcccataaaatgttttttctctttctgatAG  gacaaatattggcaaatttgacatgatttgggata …
Intron 6
Exon 7
… atttgatttttctcccataaaatgttttttctctttctggtAG  gacaaatattggcaaatttgacatgatttgggata …
 
 
Figure 11. Identification of a new TPMT polymorphism (G420-4A). Chromatograms of relevant 
DNA sequences in (a) patient and (b) healthy control; vertical lines highlight the guanine-to-
adenine mutation, present in heterozygous form (R). (c) G420-4A does not affect the acceptor site 
for splicing of exon 6 to exon 7. Part of the 3’ end of intron 6 and at the 5’ end of exon 7 are shown 
for the wild-type (top) and the SNP-containing (bottom) sequences. The acceptor splice site is 
shown in blue, the mutated nucleotide in red. 
 
3. DISTRIBUTION OF THE TPMT ALLELES ACCORDING TO AZA 
RESPONSIVENESS 
 
Analysis of the distribution of TPMT alleles into the three different groups of patients 
segregated according to their responsiveness, unresponsiveness, or intolerance to AZA, 
confirmed the presence of several known intronic and exonic TPMT polymorphisms that, 
singly, were not correlated with particular types of responses to AZA (Table 4), as also 
found in other studies. In contrast to what is generally accepted, we observed heterozygous 
TPMT*3A not associated with intolerance in two patients, one unresponsive and one 
responsive to AZA (Table 4). As shown in Table 5, the genotype distributions of the eight 
TPMT SNPs detected in our patients are all in Hardy-Weinberg equilibrium (HWE p-value 
>0.05). The new SNP, G420-4A, had a minor allele frequency (MAF) <1% of the total 
population (Table 5) and was therefore excluded from further analysis.  
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Table 4. Distribution of TPMT alleles according to AZA responsiveness 
 
Frequency as Allele AZA response Wild-type  frequency Heterozygous Homozygous 
I 30 (60%) 14 (28%) 6 (12%) 
U 16 (50%) 6 (18.8%) 10 (31.2%) A141-101T 
R 27 (45%) 15 (25%) 18 (30%) 
I 30 (60%) 14 (28%) 6 (12%) 
U 15 (46.9%) 7 (21.9%) 10 (31.2%) T366+58C 
R 26 (43.3%) 14 (23.3%) 20 (33.4%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G420-4Aa 
R 60 (100%) 0 (0%) 0 (0%) 
I 41 (82%) 7 (14%) 2 (4%) 
U 24 (75%) 4 (12.5%) 4 (12.5%) C474Tb 
R 46 (76.7%) 12 (20%) 2 (3.3%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C339Tb 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) *3A (*3B+*3C) R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 46 (92%) 4 (8%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) *3A +  T140+114A R 60 (100%) 0 (0%) 0 (0%) 
I: intolerant (n = 25); U: unresponsive (n = 16); R: responsive (n = 30); a Newly identified;  
b
 Synonymous polymorphism 
 
Table 5. TPMT SNPs identified in our cohort of patients 
 
SNPs Alleles MAF p-val HWE Gene Mutation Amino acid 
substitution 
T140+114A T/A 0.028 1 Intronic - 
A141-101T A/T 0.337 1 Intronic - 
C339T C/T 0.014 1 Synonymous None 
T366+58C C/T 0.05 1 Intronic - 
G420-4A G/A 0.007 1 Intronic - 
G460A G/A 0.042 1 Non Synonymous A/T 
C474T C/T 0.218 0.857 Synonymous None 
A719G A/G 0.042 1 Non synonymous Y/C 
Red: new intronic polymorphism 
 
4. HAPLOTYPE ASSOCIATION ANALYSIS 
 
Using Solid Spine method, we defined a linkage disequilibrium (LD) block spanning 18 kb 
for the seven relevant SNPs in the 71 patients (Figure 12). Strong evidence for pairwise 
LD was observed between T140+114A and each SNP of the *3A haplotype (G460A, 
A719G) with D’ = 1 and r2 = 0.65 (Figure 12). 
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Figure 12. Haplotype block diagram of the 18 kb TPMT region analysed in this study. The LD 
plot, as determined by Solid Spine method, defines the 18 kb TPMT in one haplotype block. 
Pairwise LD among the SNPs was examined using standard coefficient D’ (D’ = 0: blue; D' = 1: 
red) and LD coefficient expressed as r2 (numbers in rhombi). 
 
Haplotype estimation yielded eight major haplotypes, of which five had a frequency cut-
off >1% (Table 6). The test for overall distribution of haplotypes showed statistical 
differences in the distribution of haplotype frequencies between intolerant and responsive 
patients. The computed global score and haplotype-specific p-values were calculated and 
adjusted with clinical covariate (sex), under the additive model (Global simulated p-value 
= 0.0238). Unconditional regression analysis revealed that Hap5 [ATCCACG; Psim = 
0.0372, Odds Ratio (OR) = 1.67, Confidence Interval (CI) = 1.06-2.62, Table 7] was 
significantly associated with intolerance, compared with the most frequent haplotype Hap 
1 (TACTGTA; Table 6 and Table 7); the simulated p-value (Psim) was still significant 
after permutation (10000 times). 
 
Table 6. Haplotype evaluation through Expectation Maximixation algorithm. 
 
Hapa T140+ 
114A 
A141- 
101T 
C339T T366+ 
58C 
G460A C474T A719G R+I 
Freqb 
Hap1 T A C T G T A 0.430 
Hap2 T T C C G T A 0.306 
Hap3 T A C T G C A 0.079 
Hap4 T T C C G C A 0.11 
Hap5 A T C C A C G 0.036 
Hap6 T A C C G C A 0.009 
Hap7 T T T C G C A 0.009 
Hap8 T T C C A T G 0.008 
aHaplotype identified in our patients; bR+I Freq, haplotype frequency in intolerant and responder 
patient population 
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Of the five major haplotypes with a relevant frequency cut-off (>1%; Hap1-Hap5; Table 
7), two, Hap2 and Hap4, had a negative Hap-Score (Hap2 = -1.5202, Hap4 = -1.69), 
indicating that intolerance was unlikely in the presence of these haplotypes. In contrast, the 
frequency of the Hap2 and Hap4 haplotypes was high in responders, albeit not significant. 
 
Table 7. Summary of the statistics association study of relevant TPMT haplotypes 
 
Hapa R+I  
Freqb 
R  
Freqc 
I  
Freqd 
Hap- 
Scoree 
p-valf Psimg ORh CIi 
Hap1 0.430 0.404 0.420 +1.096 0.273 0.288 Base Base 
Hap2 0.306 0.346 0.300 -1.520 0.128 0.139 0.938 0.784-1.122 
Hap3 0.079 0.030 0.180 +1.308 0.191 0.220 1.430 1.071-1.905 
Hap4 0.112 0.170 9.394E-07 -1.689 0.091 0.090 0.619 0.451-0.851 
Hap5 0.036 - 0.08 +2.254 0.024 0.037 1.671 1.065-2.622 
a Haplotypes; b R+I Freq, haplotype frequency in responder and intolerant patient population;           
c R Freq, haplotype frequency in responder patients; d I Freq, haplotype frequency in intolerant 
patients; eHap-Score obtained using the haplo.score function; fp-val, p-value obtained using the 
haplo.score function; g Psim, p-value of 10000-time permutation test; h OR, Odds Ratio;                       
i CI, Confidence Interval. 
 
5. NEW INTRONIC POLYMORPHISM IN XDH GENE 
 
To identify SNPs in the XDH gene, we have used the same strategy as that used to identify 
TPMT SNPs, with primers that allow the amplification of about 50 bases of intronic 
sequences flanking the exon on each side. We found one previously undescribed 
nucleotidic change located in intron 8. The new intronic nucleotidic change (T652-21A) is 
located 21 bases upstream of exon 9 in one intolerant patient with a heterozygous genotype 
(Figure 13).  
 
  
 
Figure 13. Identification of a new intronic XDH polymorphism. (a) Chromatogram of the relevant 
DNA sequence in the intolerant patient; vertical lines highlight the thymine-to-adenine mutation, 
present in heterozygous form (W).  
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6. NEW EXONIC MUTATIONS IN XDH GENE 
 
By genotyping all the 36 exons of XDH gene, we identified three new mutations in exons 
11, 13, and 26, and one polymorphism in exon 16. 
In exon 11, we found a non-synonymous nucleotidic change c.G1004A, p.Arg335His 
present in heterozygous form in one intolerant patient. This mutation is located in the 
FAD-binding domain (Figure 14a). The occurrence of this mutation was sought, but not 
found, in 100 healthy controls. It is interesting to note that Arg at position 335 is conserved 
in higher species (Figure 14b), suggesting that it might play an important role in the 
protein; hence, a change from Arg to the cyclic His is likely to have a significant effect. 
Indeed, the FoldX algorithm revealed a positive difference in free energy of the mutated 
protein (2.8 kcal/mol), indicating that c.G1004A, p.Arg335His destabilizes the structure of 
XO (Figure 14c and Table 9).  
 
a.  c. ddG: 2.80 kcal/mol
Arginine Histidine
 
 
b. 
Homo sapiens
Pan Troglodytes
Canis lupus familiaris
Bos taurus
Mus musculus
Rattus norvegicus
Gallus gallus
Danio rerio
Drosophila melanogaster
Anopheles gambiae
Caenorhabditis elegans
Magnaporte grisea
Neurospora crassa
Arabidopsis thaliana
Arabidopsis thaliana
Oryza sativa
 
 
Figure 14. Characteristics of the c.G1004A,p.Arg335His mutation. a. Chromatogram of the 
relevant DNA region encompassing the c.G1004A sequence; vertical lines highlight the guanine-
to-adenine variant, present in heterozygous form (R); the mutation (arrow) is located in the FAD 
binding domain (blue block); b. Arginine (R) is conserved in XHD orthologs from many species; c. 
3D representation of wild-type and mutated XO structure focused on the area of the mutation; the 
ddG value is indicated. 
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 In exon 13, we found a synonymous nucleotidic change c.G1194A, p.Leu398Leu, located 
in the sequence coding for the FAD-binding domain (Figure 15), in one intolerant patient; 
hence, the mutation has no effect on the protein product (Table 9). The occurrence of this 
mutation was sought, but not found, in 100 healthy controls. 
 
 
 
Figure 15. Characteristics of the c.G1194A, p.Leu398Leu mutation. Chromatogram of the relevant 
DNA region encompassing the c.G1194A sequence; vertical lines highlight the guanine-to-adenine 
mutation, present in heterozygous form (R); the mutation (arrow) is located in the FAD-binding 
domain (blue block). 
 
In exon 16, we found the non-synonymous nucleotidic change c.C1167T, p.Ala556Val 
present in heterozygous form in one intolerant, one unresponsive, and two responsive 
patients. This polymorphism is located in the connection segment between the FAD-
binding domain and the molybdopterin domain (Figure 16a) and Ala at position 556 is 
conserved in mammalian species (Figure 16b). It is interesting to note that the occurrence 
of this polymorphism was found in 3/100 healthy controls, suggesting that it might not 
play an important role in the protein. Indeed, the FoldX algorithm showed a weakly 
negative difference in free energy of the modified protein (-0.48 kcal/mol), indicated that 
c.C1167T, p.Ala556Val, does not destabilize the structure of XO (Figure 16c and Table 
9). 
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a. 
Unresponsive Patient Responsive Patient
Responsive Patient Intolerant Patient
 b. 
Homo sapiens
Pan Troglodytes
Canis lupus familiaris
Bos taurus
Mus musculus
Rattus norvegicus
Gallus gallus
Danio rerio
Drosophila melanogaster
Anopheles gambiae
Caenorhabditis elegans
Magnaporte grisea
Neurospora crassa
Arabidopsis thaliana
Arabidopsis thaliana
Oryza sativa
 
 
c. ddG : -0.48 kcal/mol
Alanine Valine
 
Figure 16. Characteristics of c.C1167T, p.Ala556Val mutation. a. Chromatogram of relevant DNA 
region encompassing c.C1167T sequence; vertical lines highlight the cytosine-to-thymine 
polymorphism, present in heterozygous form (Y). The polymorphism is located in exon 16 (arrow) 
encoding part of the sequence of the connecting segment between the FAD-binding domain and the 
molybdopterin domain (purple block); b. Alanine (A) is conserved in XDH orthologs from many 
species; c. 3D representation of wild-type and mutated XO structure focused on the area of the 
mutation; the ddG value is indicated. 
 
In exon 26, we found a non-synonymous nucleotiditic change c.C2891T, p.Thr964Ile 
present in heterozygous form, in one responsive patient. This mutation is in the 
molybdopterin domain (Figure 17a). The occurrence of this mutation was sought, but not 
found, in 100 healthy controls. It is interesting to note that Thr at position 964 is conserved 
in higher species (Figure 17b), suggesting that it might play an important role in the 
protein, hence, a change from Thr to the Ile is likely to have a significant effect. Indeed, 
the FoldX algorithm revealed a positive difference in free energy of the mutated protein 
(2.06 kcal/mol), indicating that c.C2891T, p.Thr964Ile, destabilizes the structure of the XO 
(Figure 17c and Table 9).  
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 a.  c. ddG: 2.06 kcal/mol
Threonine Isoleucine
 
 
b. 
Homo sapiens
Pan Troglodytes
Canis lupus familiaris
Bos taurus
Mus musculus
Rattus norvegicus
Gallus gallus
Danio rerio
Drosophila melanogaster
Anopheles gambiae
Caenorhabditis elegans
Magnaporte grisea
Neurospora crassa
Arabidopsis thaliana
Arabidopsis thaliana
Oryza sativa
 
 
Figure 17. Characteristics of c.C2891T, p.Thr964Ile. a. Chromatogram of the relevant DNA region 
encompassing c. C2891T; vertical lines highlight the cytosine-to-thymine variant, present in 
heterozygous form (Y) the mutation (arrow) is located in the molybdopterin domain (pink block); 
b. threonine (T) is conserved in XHD orthologs from many species; c. 3D representation of wild-
type and mutated XO structure focused on the area of the mutation; the ddG value is indicated. 
 
7. DISTRIBUTION OF THE XDH ALLELES ACCORDING TO AZA 
RESPONSIVENESS 
 
Studies of the distribution of XDH allele into the three different groups of patients divided 
according to their responsiveness, unresponsiveness, or intolerance to AZA, verified the 
presence of some known intronic and exonic XDH polymorphisms that, singly, were not 
associated with specific types of responses to AZA (Table 8). We observed heterozygosity 
for A2107G (Table 8), a polymorphism shown by Kudo et al. to determines hyper-
activation of XO,47 albeit with no statistically significant correlation, and thereby increased 
metabolism of 6-MP to thiouric acid and, hence, decreased production of 6TGNs from 
AZA. Accordingly, the A2107G polymorphism should lead to unresponsiveness to AZA. 
In our cohort, however, this polymorphism was identified not only in 4 unresponsive 
patients, but also in one responsive and two intolerant patients. All 7 patients, regardless of 
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their status in response to AZA, show the polymorphism A2107G in association with 
another non-synonymous polymorphism, A1936G (Table 8).  
 
Table 8. Distribution of XDH alleles according to AZA responsiveness 
 
Frequency as Allele AZA response Wild-type frequency Heterozygous Homozygous 
I 47 (94%) 3 (6%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C100+27T 
R 60 (100%) 0 (0%) 0 (0%) 
I 45 (90%) 5 (10%) 0 (0%) 
U 26 (81.3%) 6 (18.75%) 0 (0%) A307-33G 
R 51 (85%) 7 (11.7%) 2 (3.3%) 
I 48 (96%) 2 (4%) 0 (0%) 
U 30 (93.8%) 2 (6.2%) 0(0%)  G514A 
R 53 (88.3%) 7 (11.7%) 0 (0%) 
I 48 (96%) 2 (4%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) G627Ab 
R 54 (90%) 6 (10%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) T652-21Aa 
R 60 (100%) 0 (0%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G822Ab 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 48 (96%) 2 (4%) 0 (0%) 
U 30 (93.8%) 2 (6.2%) 0(0%)  C837Tb 
R 54 (90%) 6 (10%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) C859G 
R 60 (100%) 0 (0%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G1004Aa 
R 60 (100%) 0 (0%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G1194Aa 
R 60 (100%) 0 (0%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C1274G 
R 60 (100%) 0 (0%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G1329Ab 
R 58 (96.7%) 2 (3.3%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C1509Gb 
R 60 (100%) 0 (0%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C1667Ta 
R 58 (96.7%) 2 (3.3%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) G1857-4A 
R 60 (100%) 0 (0%) 0 (0%) 
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I 48 (96%) 2 (4%) 0 (0%) 
U 28 (87.5%) 4 (12.5%) 0 (0%) A1936G 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 48 (96%) 2 (4%) 0 (0%) 
U 28 (87.5%) 4 (12.5%) 0 (0%) A2107G 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 37 (74%) 9 (18%) 4 (8%) 
U 28 (87.5%) 4 (12.5%) 0 (0%) G2197+42C 
R 41 (68.3%) 11 (18.3%) 8 (13.4%) 
I 31 (62%) 13 (26%) 6 (12%) 
U 19 (59.4%) 9 (28.1%) 4 (12.5%) G2197+68A 
R 46 (76.7%) 10 (16.7%) 4 (6.6%) 
I 38 (76%) 8 (16%) 4 (8%) 
U 29 (90.6%) 3 (9.4%) 0 (0%) C2211Tb 
R 46 (76.7%) 8 (13.3%) 6 (10%) 
I 10 (20%) 6 (12%) 34 (68%) 
U 8 (25%) 6 (18.7%) 18 (56.3%) A2544+35T 
R 23 (38.3%) 13 (21.7%) 24 (40%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G2824-35A 
R 58 (96.7%) 2 (3.3%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) C2891Ta 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 12 (24%) 8 (16%) 30 (60%) 
U 10 (31.2%) 8 (25%) 14 (43.8%) T3030Cb 
R 17 (28.3%) 13 (21.7%) 30 (50%) 
I 13 (26%) 7 (14%) 30 (60%) 
U 10 (31.2%) 8 (25%) 14 (43.8%) C3052-12G 
R 16 (26.7%) 12 (20%) 32 (53.3%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 30 (93.8%) 2 (6.2%) 0 (0%) A3352-21C 
R 54 (90%) 2 (3.3%) 4 (6.7%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) T3488C 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) T3536C 
R 60 (100%) 0 (0%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) G3717Ab 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 49 (98%) 1 (2%) 0 (0%) 
U 31 (96.9%) 1 (3.1%) 0 (0%) C3774+32G 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 50 (100%) 0 (0%) 0 (0%) 
U 32 (100%) 0 (0%) 0 (0%) C3886T 
R 59 (98.3%) 1 (1.7%) 0 (0%) 
I 20 (40%) 10 (20%) 20 (40%) 
U 22 (68.8%) 8 (25%) 2 (6.2%) A4002+518G 
R 36 (60%) 14 (23.3%) 10 (16.7%) 
I 38 (76%) 10 (20%) 2 (4%) 
U 20 (62.5%) 8 (25%) 4 (12.5%) A4002+1477G 
R 40 (66.7%) 14 (23.3%) 6 (10%) 
36 
I 20 (40%) 12 (24%) 18 (36%) 
U 22 (68.8%) 8 (25%) 2 (6.2%) C4002+1516T 
R 39 (65%) 11 (18.3%) 10 (16.7%) 
I 40 (80%) 8 (16%) 2 (4%) 
U 24 (75%) 6 (18.7%) 2 (6.3%) G4002+1555T 
R 43 (71.7%) 9 (15%) 8 (13.3%) 
I: intolerant (n = 25); U: unresponsive (n = 16); R: responsive (n = 30); a Newly identified; b 
Synonymous polymorphism 
 
As shown in Table 9, the genotype distributions of the thirty-five XDH nucleotidic 
changes detected in our patients, including the four new mutations and polymorphism we 
have demonstrated, are all in Hardy-Weinberg equilibrium (HWE p-value >0.05), with 
exception of the intronic A3352-30C, which was excluded from subsequent analysis. Of 
these 35 changes, the following 12 SNPs and mutations, T652-21A, G822A, C859G, 
G1004A, G1194A, C1274G, C1509G, G1857-4A, C2891T, T3488C, T3536C, and 
C3886T, were also excluded from further analysis as they had a minor allele frequency 
(MAF) <1% of the total population (Table 9). 
 
Table 9. XDH nucleotidic changes identified in our cohort of patients 
 
SNPs Allele MAF 
p-Val  
HWE Gene mutation 
Amino acid  
substitution 
Protein 
destabilization  
C100+27T C/T 0.035 1 Intronic - - 
A307-33G A/G 0.141 1 Intronic - - 
G514A G/A 0.077 1 Non Synonymous G/R - 
G627A G/A 0.063 1 Synonymous None - 
T652-21A T/A 0.007 1 Intronic - - 
G822A G/A 0.007 1 Synonymous None - 
C837T C/T 0.07 1 Synonymous None - 
C859G C/G 0.007 1 Non Synonymous L/V - 
G1004A G/A 0.007 1 Non Synonymous R/H Yes 
G1194A G/A 0.007 1 Synonymous None No 
C1274G C/G 0.007 1 Non Synonymous S/C - 
G1329A G/A 0.014 1 Synonymous None - 
C1509G C/G 0.007 1 Synonymous None - 
C1667T C/T 0.028 1 Non Synonymous A/V Yes 
G1857-4A G/A 0.007 1 Intronic - - 
A1936G A/G 0.049 1 Non Synonymous I/V - 
A2107G A/G 0.049 1 Non Synonymous I/V - 
G2197+42C G/C 0.254 0.51 Intronic - - 
G2197+68A G/A 0.324 1 Intronic - - 
C2211T C/T 0.204 0.24 Synonymous None - 
A2544+35T T/A 0.289 0.33 Intronic - - 
G2824-35A G/A 0.014 1 Intronic - - 
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C2891T C/T 0.007 1 Non Synonymous T/I  
T3030C C/T 0.275 1 Synonymous None  
C3052-12G G/C 0.275 0.87 Intronic -  
A3352-30C A/C 0.063 0.04 Intronic -  
T3488C T/C 0.007 1 Non Synonymous V/A  
T3536C T/C 0.007 1 Non Synonymous I/T  
G3717A G/A 0.014 1 Synonymous None  
C3774+32G C/G 0.021 1 Intronic -  
C3886T C/T 0.007 1 Non Synonymous R/W  
A4002+518G A/G 0.451 0.56 3’UTR -  
A4002+1477G A/G 0.31 0.92 3’UTR -  
C4002+1516T C/T 0.43 0.46 3’UTR -  
G4002+1555T G/T 0.246 0.40 3’UTR -  
In red: newly detected mutations and polymorphisms 
 
8. HAPLOTYPE ASSOCIATION ANALYSIS 
 
Using the Solid Spine method, we defined a four LD blocks spanning 71.5 kb for the 21 
relevant SNPs in the 71 patients (Figure 18). 
 
 
 
Figure 18. Haplotype block diagram of the 71.5 kb XDH gene region analyzed in this study. The 
LD plot, as determined by Solid Spine method, defines the 71.5 kb XDH in four haplotype blocks. 
Pairwise LD among the SNPs was examined using standard coefficient D’ (D’ = 0: blue; D' = 1: 
red; 0> D’ <1: other colours) and LD coefficient expressed as r2 (numbers in rhombi). 
100 
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The Spine algorithm defined four LD blocks within the 71.5 kb XDH gene region analyzed 
in this study. Haplotype estimation showed that, of all four LD blocks, only block 4 
contains a haplotype significantly associated with intolerance. Thus, haplotype evaluation 
yielded seven major haplotypes within block 4, as per a frequency cut-off >1% (Table 10); 
of these, unconditional regression analysis revealed that Hap6 (CGATG; PSim = 0.017, 
Table 11) was significantly associated with intolerance, compared to the second most 
frequent haplotype Hap4 (CAGCT; Table 10 and Table 11); Psim was still significant 
after permutation (10000 times). The computed global score and haplotype-specific p-
values were calculated and adjusted with clinical covariate (sex), under the additive model 
(Global simulated p-value = 0.241). 
Of the seven major haplotypes estimated (Hap1-Hap7; Table 10), two, Hap3 and Hap5, 
had a negative Hap-Score (cut-off > -1; Hap3 = -1.257, Hap5 = -1.479), indicating that 
intolerance was unlikely in the presence of these haplotypes. In contrast, the frequencies of 
the Hap3 and Hap5 haplotypes were high in responders, albeit not significant. 
 
Table 10. Haplotype evaluation through Expectation Maximixation algorithm. 
 
Hapa 
C3774+ 
32G 
A4002+ 
518G 
A4002+ 
1477G 
C4002+ 
1516T 
G4002+ 
1555T 
R+I  
Freqb 
Hap1 C A A C G 0.198 
Hap2 C A A C T 0.021 
Hap3 C A G C G 0.074 
Hap4 C A G C T 0.206 
Hap5 C G A C G 0.018 
Hap6 C G A T G 0.445 
Hap7 C G G C T 0.010 
aHaplotype identified in our patients; bFrequency of haplotype in our cohort 
 
Table 11. Summary of statistics association study of XDH haplotypes 
 
Hapa 
R+I  
Freqb 
R  
Freqc 
I  
Freqd 
Hap- 
Scoree 
p-valf Psimg ORh CIi 
Hap1 0.198 0.230 0.160 -0.909 0.363 0.377 1.087 0.815-1.450 
Hap2 0.021 0.037 - -0.972 0.331 0.609 0.871 0.520-1.458 
Hap3 0.074 0.103 0.040 -1.257 0.209 0.190 0.844 0.566-1.258 
Hap4 0.206 0.230 0.180 -0.636 0.525 0.603 Base Base 
Hap5 0.018 0.033 - -1.479 0.139 0.208 0.702 0.340-1.445 
Hap6 0.445 0.333 0.580 +2.391 0.017 0.017 1.229 0.968-1.561 
Hap7 0.010 - 0.020 +0.978 0.328 0.658 1.636 0.600-4.460 
a Haplotypes; b R+I Freq, haplotype frequency in responder and intolerant patient population;           
c R Freq, haplotype frequency in responder patients; d I Freq, haplotype frequency in intolerant 
patients; e Hap-Score obtained using the haplo.score function; f p-val, p-value obtained using the 
haplo.score function; g Psim, p-value of 10000-time permutation test; h OR, Odds Ratio;                   
i CI, Confidence Interval. 
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DISCUSSION 
 
Azathioprine is one of the most widely used immunosuppressant drugs for the treatment of 
many different diseases such as inflammatory bowel disease, Crohn’s disease, ulcerative 
colitis,3 rheumatologic diseases,2 rheumatoid arthritis,79 myasthenia gravis80,81 and multiple 
sclerosis.82 In autoimmune diseases, AZA is often administered as a steroid-sparing 
drug.81,83-86 However, responsiveness to the drug differs in different patients, and the 
possibility to predict unresponsiveness and/or intolerance is of outmost importance for safe 
and effective treatment. There is increasing evidence from pharmacogenetics studies that 
hereditary changes in genes coding for TPMT and XO can affect the response to AZA,87 
by altering the functionality of these enzymes or determining their rapid degradation.88 
Towards further delineation of genetic TPMT and XDH polymorphisms that might be 
specifically associated with the different types of response to AZA and could thereby be 
used as part of pharmacogenetic profiles to identify intolerant and/or unresponsive patients, 
we have genotyped 71 Italian patients treated with AZA. 
Through these studies, we uncovered new intronic polymorphisms, one in TPMT, G420-
4A, and one in XDH, T652-21A. Each polymorphism was carried by one different AZA-
intolerant patient, with TPMT G420-4A also detected in one of 100 healthy controls 
investigated. As these nucleotidic changes are located four bases upstream of the RNA 
splicing site for exon 7 of TPMT gene and 21 bases upstream of the RNA splicing site for 
exon 9 of XDH gene, we hypothesize that they could affect mRNA splicing,89,90 thus 
coding for truncated proteins with defective enzymatic activity. However, G420-4A splice 
site prediction indicated that the polymorphism does not affect the relevant acceptor site, 
nor does it create a new splicing site. Nevertheless, we cannot exclude that TPMT G420-
4A could interfere with the protein of the spliceosome that binds upstream of exon 7 in the 
region of the acceptor site.91-93 Similarly, XDH T652-21A could affect the association of 
the small nuclear RNA–protein complex U2 with the branch point region of the intron, 
located 20 - 50 bases upstream of the splice acceptor site;94,95 both polymorphisms 
therefore have the potential to affect mRNA splicing and the protein product. Since the 
variants (TPMT G420-4A and XDH T652-21A) were each found only in one AZA-treated 
patient, further studies in larger cohorts of varying ethnicities are necessary to evaluate 
their frequency in the general population. Such studies would also permit to better 
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understand if intolerance to AZA in the patients was indeed related to alteration of the 
TPMT or XO enzymes imparted by these nucleotidic changes. 
Through genotyping of the TMPT gene, we detected a novel haplotype defined by seven 
SNPs, which include both SNPs of TPMT*3A and which we have termed TPMT*3E. 
TPMT*3E was significantly associated with intolerance in our population (Table 7, Psim = 
0.037), and none of the 16 unresponsive or 30 responsive patients carried this novel 
haplotype. The T140+114A polymorphism was found in our cohort only in association 
with the TPMT*3A mutations, as part of TPMT*3E (4/25 intolerant patients); none of the 
patients carried this SNP on its own. At present, it is not possible to ascertain if the 
presence of the T140+114A polymorphism amplifies the intolerant response to the drug 
that is associated with mutations encompassed in TPMT*3A. Studies on larger cohorts will 
be needed to determine whether this SNP is always found as part of the TPMT*3E 
haplotype or also occurs alone, and if so, whether it could by itself be associated with 
intolerance; in this context, the study of Otterness et al., who first reported this SNP, is not 
clear.38 Larger, diverse, cohorts are also necessary to investigate ethnic variations in 
frequency of TPMT*3E or the single T140+114A polymorphism. Indeed, the frequency of 
TPMT alleles in different ethnic groups varies greatly; for example, TPMT*3A, which is 
the most prominent allele in Caucasians, was not found in Ghanaian and Korean 
individuals,96-98 and the frequency of TPMT*3C, the most prominent allele in Ghanaian 
and Korean individuals, is very low in Caucasians.99 We could only find reports for 
T140+114A frequencies for two different populations in the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3931660): 6% for a Nigerian 
cohort of 25 individuals and 9.4% for a cohort of 90 individuals whose ethnic origin is not 
reported. It is therefore difficult to discuss if the allele frequency for T140+114A in our 
AZA-treated Italian cohort (3.2%) is commensurate with that of other populations. 
Strikingly, whereas the TPMT*3A haplotype was seen also in the context of 
unresponsiveness or responsiveness in our cohort, none of the unresponsive or responsive 
patients carried the TPMT*3E haplotype. This could suggest a very strong link of 
TPMT*3E with AZA intolerance. The TPMT*3A haplotype has been linked to intolerance 
to AZA87 and appears to be the most frequent inactivating mutant allele in Caucasians (3.2-
5.7%),96,100,101 including Italian subjects (3.9%).102 In our cohort, the percentage of patients 
heterozygous for TPMT*3A mutations was over twice as high (6/71 patients; 8.5%), a 
difference that could be related to the small cohort studied. TPMT*3A has not so far been 
reported in association with responsiveness or unresponsiveness. In our study, however, 
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the TPMT*3A haplotype was detected in one unresponsive patient and in one apparently 
responsive patient by DNA sequencing (Table 4). This responsive TPMT*3A patient was 
given AZA as a steroid-sparing agent. Whether or not steroid-sparing in this TPMT*3A 
patient was directly correlated to AZA treatment is not absolutely established. 
Nevertheless, after eleven years of AZA treatment, the patient’s daily steroid dose had 
been reduced to over 80% from the initial dose. Neither this patient, nor the unresponsive 
one, experienced side effects as might be expected in individuals carrying the TPMT*3A 
allele.32 The unexpected occurrence of TPMT*3A in association with unresponsiveness or 
responsiveness in our cohort could be related to one or more additional unknown variants 
in TPMT or in other genes of AZA metabolism that would abrogate the effect of the 
TPMT*3A allele and, although such an effect has never been demonstrated, could lead to 
hyperactivity of the enzyme in the unresponsive patient. 
Similarly, the XDH A2107G polymorphism, which has been associated with hyper-
activation of XO47 and should therefore lead to unresponsiveness to AZA, was detected in 
two intolerant and one responsive patients, in addition to four unresponsive patients. LD 
analysis showed that this mutation is strongly associated with A1936G (r2=100) in all these 
seven patients; indeed, neither mutation was found in the other 64 patients. Unfortunately, 
how the XDH A1936G polymorphism affects XO activity is not known, nor are possible 
associations of A1936G with other XDH polymorphisms. Obviously, however, as all seven 
patients with different responses to AZA bore both polymorphisms, it is unclear if either, 
both, or neither affect response to AZA; indeed, the different types of responses could also 
be due to other single genetic changes or combinations with XDH A2107G and/or A1936G 
polymorphisms (see below), and/or polymorphisms in other relevant genes. Unexpected 
effect of polymorphisms in TPMT or XDH could also be mediated at genomic level via 
epistasis by modifier genes.103,104 Another possibility would involve a variation in GST 
resulting in reduced or increased enzymatic activity, and thereby only little or high 
conversion of AZA to 6-MP, hence unresponsiveness or intolerance, irrespective of 
mutations that might affect TPMT and XO downstream of GST in the pathway. Finally, 
unresponsiveness could be accounted for by variation(s) in AOX1 coding for aldehyde 
oxidase, which contributes to the catabolism of AZA, MP, and other thiopurine 
metabolites. Indeed, the presence of a coding-region SNP in AOX1 is significantly 
associated with lack of therapeutic response to AZA, which in this case is apparently not 
related to differences in TGN levels.99 
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Through genotyping of the XDH gene, we detected two novel non-synonymous mutations 
(c.G1004A, p.Arg335His; c.C2891T, p.Thr964Ile), one new synonymous mutation 
(c.G1194A, p.Leu398Leu) and one novel non-synonymous polymorphism (c.C1167T, 
p.Ala556Val). The first new missense mutation, c.G1004A, p.Arg335His, identified in one 
intolerant patient was located in the FAD-binding domain. This domain is one of the three 
active sites of XO protein.58 A change of Arg for His at position 335, which is conserved in 
higher species, is likely to have an effect on the structural conformation of the FAD-
binding domain. Indeed, while both are hydrophilic and basic amino acids, histidine 
contains an imidazole group, an aromatic ring that can lead to steric hindrance, thereby 
destabilizing the protein structure. Such possible effect of the mutation is confirmed by the 
positive score obtained with FoldX algorithm105 predicting instability of the mutated XO 
protein. This could therefore lead to decreased XO activity, for example through increased 
protein degradation or through deficient binding of FAD, hence reduced efficiency of the 
enzyme function, and thereby intolerance to azathioprine. 
The second novel non-synonymous mutation, c.C2891T, p.Thr964Ile, was found in one 
responsive patient (Table 8). This mutation was located in the molybdopterin domain, 
another active site of XO protein.58 The mutation results in a change of Thr, a hydrophilic 
amino acid conserved in higher species, to Ile, a hydrophobic amino acid, at position 964. 
The replacement of a hydrophilic amino acid with a hydrophobic amino acid is likely to 
have a profound effect on the molybdopterin domain structure and consequently on XO 
activity. This was confirmed by the positive score obtained with FoldX algorithm 
predicting instability of the mutated XO protein. Unexpectedly, the c.C2891T, p.Thr964Ile 
mutation occurred in association with responsiveness, suggesting that the destabilizing 
effect on the protein did not in fact affect the enzymatic activity; indeed, it is likely that, in 
this case, the structural change imparted by the mutation does not lead to release of the 
molybdenum ion. Alternatively, we cannot exclude that responsiveness in the presence of a 
potentially destabilizing mutation could be related to one or more additional unknown 
variants in other genes of AZA metabolism that would abrogate the effect of this 
mutation.103 
The non-synonymous polymorphism, c.C1167T, p.Ala556Val, uncovered in one intolerant, 
one unresponsive, two responsive patients (Table 8), and 3/100 healthy controls causes an 
amino acid change in the connection segment between the FAD-binding and 
molybdopterin domains, a polymorphic domain of the protein. The change of Ala to Val at 
position 556 is unlikely to have a significant effect on the protein, and thereby should not 
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alter XO activity. Indeed, Ala and Val are small, hydrophobic amino acids that can 
generally substitute for each other without affecting the physico-chemical characteristics of 
a protein. This was confirmed by FoldX algorithm calculation, which gave a weakly 
negative score for the mutated protein. Finally, the silent mutation, c.G1194A, 
p.Leu398Leu, identified in an intolerant patient should not cause functional impairment of 
XO. These predictions need to be validated through studies of the enzymatic function of 
XO in individuals with the relevant mutations. 
LD analysis of XDH identified 4 different blocks, one of which was significantly 
associated with intolerance in our population (Table 11 Psim = 0.017). It includes five 
SNPs, one intronic and four located in the 3' untranslated regions (3' UTRs). As the 3’UTR 
is important for RNA processing, one possible effect of the SNPs would be through 
interference in polyadenylation and thereby mRNA maturation. Processing of the pre-
mRNA involves post-transcriptional cleavage of the 3′ ends that occurs at a specific site 
located 15 – 30 nucleotides downstream of a cleavage signal, with the sequence, 
AAUAAA.106 Addition of the polyA tail resulting in a mature mRNA occurs at the 
cleavage site. However, in XDH pre-mRNA, one SNP found in the 3’ UTRs is located 20 
base pairs upstream of the cleavage signal AAUAAA and the other three SNPs are located 
around 900 - 1000 base pairs downstream of the cleavage site; accordingly, these SNPs are 
contained one before cleavage signal and three in the cleaved region and are therefore 
unlikely to have any effect on polyadenylation and thereby on mRNA maturation. Another 
possibility could be that the SNPs located in the 3’ UTR affect the regulation of protein 
expression through alteration of the target sites for microRNAs, small ribonucleic acid 
molecules, that interact with the 3' UTRs to regulate the expression of mRNAs.107 This 
could therefore lead to AZA intolerance in our patients, through in an increase in down-
regulation of XDH mRNA and thereby XO expression. Obviously, such a hypothesis needs 
to be explored experimentally. 
While the association of the new TPMT*3E and XDH 3’UTR haplotype with intolerance to 
AZA must be further delineated, these studies confirm the relevance of establishing 
pharmacogenetic profiles for specific drugs, especially those that can result in severe side 
effects, to determine their suitability in individual patients. Indeed, through such analysis, 
we could make preliminary distinction between the seven patients who showed diverse 
responses to AZA, albeit bore the same XHD SNP (A2107G associated with A1936G) that 
has been associated with hyperactivity of XO, and should therefore all have shown 
unresponsiveness to AZA (Table 12). Thus, as shown in Table 12, while none of the 
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patients bore the TPMT*3E haplotype, they could be differentiated according to presence 
or absence of four particular SNPs and/ or the XDH 3’ UTR haplotype (Table 12). Thus, 
the four AZA-unresponsive patients did not have the XDH 3’ UTR haplotype, were 
heterozygous for the intronic A307-33G, and wild-type for C1667T, C2211T and the 
intronic G2197+42C; the AZA-responsive patient, while homozygous for the XDH 3’ UTR 
haplotype, was wild-type for A307-33G and C1667T, and heterozygous for G2197+42C 
and C2211T. The two intolerant patients differed in their profiles, with one patient 
homozygous for the XDH 3’ UTR haplotype and wild-type for all four SNPs, while the 
other patient, who did not bear the XDH 3’ UTR haplotype, differed from all other six 
patients by heterozygosity of C1667T. Obviously, further studies with larger cohorts are 
required to confirm and establish these profiles in the context of specific responses to 
AZA.  
 
Table 12: Study of TPMT haplotype, XDH SNPs in 7 patients with polymorphism caused XO 
hyper-activation. 
 
XDH Pa AZA  
 
Resp 
TPMT 
 
*3E A1936G A2107Gc 
3’UTR 
Hapc C1667Td 
A307 
-33G 
G2197 
+42C C2211Te 
P1 U - Het Het - wt Het wt wt 
P2 U - Het Het - wt Het wt wt 
P3 U - Het Het - wt Het wt wt 
P4 U - Het Het - wt Het wt wt 
P5 R - Het Het + wt wt Het Het 
P6 I - Het Het + wt wt wt wt 
P7 I - Het Het - Het Het Het Het 
I: intolerant; U: unresponsive; R: responsive; wt: wild-type; Het: heterozygous; +: presence of the 
haplotype; -: absence of haplotype; a P: patient; b Mutation causing XO hyper-activation; c 3’UTR 
Hap: 3’UTR haplotype; d New mutation identified in this study; e Synonymous mutation. 
 
The data obtained in the studies presented in this thesis should be analyzed statistically for 
both TPMT and XDH genes together, to establish if profiles that incorporate data from both 
genes are superior to single SNP analysis in predicting types of response to AZA. In 
addition, and using larger cohorts, pharmacogenetic profiling for AZA should not only 
include studies on TPMT and XDH, but also incorporate studies on all the other genes of 
the AZA metabolic pathways that could play a role in the response to AZA, in particular 
the genes coding for GST and aldehyde oxidase, which, respectively, convert AZA into 6-
MP and detoxify the drug.99,108,109 Indeed, these, which are key enzymes in determining 
responsiveness, unresponsiveness or intolerance, represent future targets for our 
pharmacogenetics studies of the response to AZA. 
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APPENDIX 1 
 
Summary of detected intronic and exonic TPMT SNPsa 
 
Int 3 Ex 5 Int 5 Int 6 Exon 7 Exon 10 P AZA 
response T140+ 
114A 
A141- 
101T C339T 
T366+ 
58C 
G420- 
4A G460A C474T A719G 
P1 I wt het wt het wt wt het wt 
P2 I wt het wt het wt wt het wt 
P3 I wt wt wt wt wt wt wt wt 
P4 I wt wt wt wt wt wt wt wt 
P5 I wt wt wt wt wt wt het wt 
P6 I wt het wt het wt wt het wt 
P7 I wt wt wt wt wt wt wt wt 
P8 I wt hom wt hom wt wt wt wt 
P9 I het hom wt hom wt het wt het 
P10 I wt het wt het wt wt wt wt 
P11 I het het wt het wt het wt het 
P12 I het het wt het wt het wt het 
P13 I wt het wt het wt wt het wt 
P14 I wt het wt het wt wt het wt 
P15 I wt het wt het wt wt wt wt 
P16 I wt hom wt hom wt wt wt wt 
P17 I wt het wt het wt wt wt wt 
P18 I wt het wt het het wt wt wt 
P19 I het het wt het wt het wt het 
P20 I wt wt wt wt wt wt wt wt 
P21 I wt wt wt wt wt wt het wt 
P22 I wt het wt het wt wt wt wt 
P23 I wt wt wt wt wt wt wt wt 
P24 I wt wt wt wt wt wt hom wt 
P25 I wt het wt het wt wt wt wt 
P26 U wt het wt het wt wt wt wt 
P27 U wt wt wt het wt wt hom wt 
P28 U wt hom wt hom wt het wt het 
P29 U wt het wt het wt wt het wt 
P30 U wt wt wt wt wt wt het wt 
P31 U wt hom het hom wt wt het wt 
P32 U wt het wt het wt wt wt wt 
P33 U wt het wt het wt wt het wt 
P34 U wt hom wt hom wt wt wt wt 
P35 U wt het wt het wt wt hom wt 
P36 U wt wt wt wt wt wt wt wt 
P37 U wt hom wt hom wt wt wt wt 
P38 U wt het wt het wt wt wt wt 
P39 U wt wt wt wt wt wt wt wt 
P40 U wt wt wt wt wt wt wt wt 
P41 U wt hom wt hom wt wt wt wt 
P42 R wt wt wt wt wt wt wt wt 
P43 R wt hom wt hom wt het wt het 
P44 R wt wt wt wt wt wt wt wt 
P45 R wt hom wt hom wt wt wt wt 
P46 R wt het wt het wt wt het wt 
P47 R wt het wt het wt wt het wt 
P48 R wt het wt het wt wt het wt 
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Int 3 Ex 5 Int 5 Int 6 Exon 7 Exon 10 P AZA 
response T140+ 
114A 
A141- 
101T C339T 
T366+ 
58C 
G420- 
4A G460A C474T A719G 
P49 R wt het wt het wt wt wt wt 
P50 R wt het wt het wt wt hom wt 
P51 R wt het wt het wt wt het wt 
P52 R wt het wt het wt wt het wt 
P53 R wt hom wt hom wt wt het wt 
P54 R wt hom wt hom wt wt het wt 
P55 R wt hom wt hom wt wt het wt 
P56 R wt het wt het wt wt wt wt 
P57 R wt hom wt hom wt wt wt wt 
P58 R wt wt wt wt wt wt wt wt 
P59 R wt hom wt hom wt wt het wt 
P60 R wt het wt het wt wt wt wt 
P61 R wt het wt het wt wt wt wt 
P62 R wt wt wt wt wt wt wt wt 
P63 R wt hom wt hom wt wt wt wt 
P64 R wt het het het wt wt het wt 
P65 R wt het wt hom wt wt het wt 
P66 R wt wt wt wt wt wt wt wt 
P67 R wt het wt het wt wt wt wt 
P68 R wt het wt het wt wt het wt 
P69 R wt wt wt wt wt wt wt wt 
P70 R wt het wt het wt wt wt wt 
P71 R wt hom wt hom wt wt wt wt 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Int: intron;  
Ex: exon; het: heterozygous; hom: homozygous; wt: wild type. 
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APPENDIX 2 
 
Summary of detected exonic XDH SNPs (Exon 7 - Exon 13)a  
 
Ex 7 Ex 8 Ex 10 Ex 11 Ex 13 P 
 
AZA 
response G514A G627A G822A C837T C859G G1004A G1194A 
P1 I wt wt wt wt wt wt wt 
P2 I wt wt wt wt wt wt wt 
P3 I wt wt wt wt wt wt wt 
P4 I wt wt wt wt wt wt wt 
P5 I wt wt wt wt wt wt wt 
P6 I wt wt wt wt wt wt wt 
P7 I wt wt wt wt wt wt wt 
P8 I wt wt wt wt wt wt wt 
P9 I wt wt wt wt wt wt wt 
P10 I het het wt het wt wt wt 
P11 I wt wt wt wt het wt wt 
P12 I het het wt het wt wt wt 
P13 I wt wt wt wt wt wt wt 
P14 I wt wt wt wt wt wt wt 
P15 I wt wt wt wt wt wt wt 
P16 I wt wt wt wt wt wt wt 
P17 I wt wt wt wt wt wt wt 
P18 I wt wt wt wt wt wt wt 
P19 I wt wt wt wt wt wt wt 
P20 I wt wt wt wt wt wt het 
P21 I wt wt wt wt wt het wt 
P22 I wt wt wt wt wt wt wt 
P23 I wt wt wt wt wt wt wt 
P24 I wt wt wt wt wt wt wt 
P25 I wt wt wt wt wt wt wt 
P26 U wt wt wt wt wt wt wt 
P27 U wt wt wt wt wt wt wt 
P28 U wt wt wt wt wt wt wt 
P29 U wt wt wt wt wt wt wt 
P30 U wt wt wt wt wt wt wt 
P31 U wt wt wt wt wt wt wt 
P32 U wt wt wt wt wt wt wt 
P33 U wt wt wt wt wt wt wt 
P34 U wt wt wt wt wt wt wt 
P35 U het wt wt het wt wt wt 
P36 U het het wt het wt wt wt 
P37 U wt wt wt wt wt wt wt 
P38 U wt wt wt wt wt wt wt 
P39 U wt wt wt wt wt wt wt 
P40 U wt wt wt wt wt wt wt 
P41 U wt wt wt wt wt wt wt 
P42 R wt wt wt wt wt wt wt 
P43 R wt wt wt wt wt wt wt 
P44 R wt wt wt wt wt wt wt 
P45 R wt wt wt wt wt wt wt 
P46 R wt wt wt wt wt wt wt 
P47 R wt wt wt wt wt wt wt 
P48 R wt wt wt wt wt wt wt 
P49 R wt wt wt wt wt wt wt 
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Ex 7 Ex 8 Ex 10 Ex 11 Ex 13 P 
 
AZA 
response G514A G627A G822A C837T C859G G1004A G1194A 
P50 R wt wt wt wt wt wt wt 
P51 R wt wt wt het wt wt wt 
P52 R wt wt wt wt wt wt wt 
P53 R wt wt wt wt wt wt wt 
P54 R wt wt wt wt wt wt wt 
P55 R wt wt wt wt wt wt wt 
P56 R het het wt het wt wt wt 
P57 R het wt wt het wt wt wt 
P58 R wt wt wt wt wt wt wt 
P59 R het het het wt wt wt wt 
P60 R wt wt wt wt wt wt wt 
P61 R het het wt het wt wt wt 
P62 R wt wt wt wt wt wt wt 
P63 R wt wt wt wt wt wt wt 
P64 R wt wt wt wt wt wt wt 
P65 R het het wt het wt wt wt 
P66 R het het wt het wt wt wt 
P67 R wt wt wt wt wt wt wt 
P68 R wt wt wt wt wt wt wt 
P69 R wt wt wt wt wt wt wt 
P70 R wt wt wt wt wt wt wt 
P71 R het het wt wt wt wt wt 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Ex: exon;  
het: heterozygous; hom: homozygous; wt: wild type. 
 
Summary of detected exonic XDH SNPs (Exon 14 - Exon 21)a  
 
Ex 14 Ex 15 Ex 16 Ex 18 Ex 20 Ex 21 P AZA 
Response C1274G G1329A C1509G C1667T A1936G A2107G C2211T 
P1 I wt wt wt wt wt wt wt 
P2 I wt wt wt het het het het 
P3 I wt wt wt wt wt wt het 
P4 I wt wt wt wt wt wt wt 
P5 I wt wt wt wt wt wt wt 
P6 I wt wt wt wt wt wt wt 
P7 I wt wt wt wt wt wt hom 
P8 I wt wt wt wt wt wt wt 
P9 I wt wt wt wt wt wt het 
P10 I wt wt wt wt wt wt wt 
P11 I wt wt wt wt wt wt wt 
P12 I wt wt wt wt wt wt wt 
P13 I wt wt wt wt wt wt wt 
P14 I wt wt wt wt wt wt het 
P15 I wt wt wt wt wt wt hom 
P16 I wt wt wt wt wt wt het 
P17 I wt wt wt wt wt wt wt 
P18 I wt wt wt wt wt wt wt 
P19 I wt wt wt wt wt wt wt 
P20 I wt wt wt wt wt wt het 
P21 I wt wt wt wt wt wt het 
P22 I wt wt wt wt het het wt 
P23 I wt wt wt wt wt wt wt 
P24 I wt wt wt wt wt wt het 
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Ex 14 Ex 15 Ex 16 Ex 18 Ex 20 Ex 21 P AZA 
Response C1274G G1329A C1509G C1667T A1936G A2107G C2211T 
P25 I wt wt wt wt wt wt wt 
P26 U wt wt wt wt wt wt wt 
P26 U wt wt wt wt wt wt wt 
P27 U wt wt het wt wt wt wt 
P28 U wt wt wt wt wt wt wt 
P29 U wt wt wt wt wt wt wt 
P30 U wt wt wt wt het het wt 
P31 U het wt wt wt het het wt 
P32 U wt wt wt wt wt wt wt 
P33 U wt wt wt wt wt wt het 
P34 U wt wt wt wt wt wt wt 
P35 U wt wt wt wt wt wt wt 
P36 U wt wt wt wt wt wt het 
P37 U wt wt wt wt wt wt het 
P38 U wt wt wt het wt wt wt 
P39 U wt wt wt wt wt wt wt 
P40 U wt wt wt wt het het wt 
P41 U wt wt wt wt het het wt 
P42 R wt wt wt wt wt wt wt 
P43 R wt wt wt wt wt wt wt 
P44 R wt wt wt wt wt wt het 
P45 R wt wt wt wt wt wt wt 
P46 R wt wt wt wt wt wt wt 
P47 R wt wt wt wt het het het 
P48 R wt wt wt wt wt wt wt 
P49 R wt wt wt wt wt wt wt 
P50 R wt wt wt wt wt wt hom 
P51 R wt wt wt wt wt wt hom 
P52 R wt wt wt wt wt wt het 
P53 R wt wt wt wt wt wt wt 
P54 R wt wt wt wt wt wt het 
P55 R wt wt wt het wt wt wt 
P56 R wt wt wt wt wt wt wt 
P57 R wt wt wt wt wt wt wt 
P58 R wt wt wt wt wt wt het 
P59 R wt wt wt wt wt wt het 
P60 R wt wt wt wt wt wt wt 
P61 R wt het wt wt wt wt wt 
P62 R wt wt wt wt wt wt wt 
P63 R wt wt wt wt wt wt wt 
P64 R wt wt wt het wt wt wt 
P65 R wt wt wt wt wt wt wt 
P66 R wt wt wt wt wt wt wt 
P67 R wt wt wt wt wt wt het 
P68 R wt het wt wt wt wt wt 
P69 R wt wt wt wt wt wt het 
P70 R wt wt wt wt wt wt wt 
P71 R wt wt wt wt wt wt hom 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Ex: exon; 
het: heterozygous; hom: homozygous; wt: wild type. 
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Summary of detected exonic XDH SNPs (Exon 26 - Exon 34)a 
 
Ex 26 Ex 27 Ex 32 Ex 33 Ex 34 P AZA 
Response C2891T T3030C T3488C T3536C G3717A 
P1 I wt hom wt wt wt 
P2 I wt het wt wt wt 
P3 I wt hom wt wt wt 
P4 I wt het wt wt wt 
P5 I wt het wt wt wt 
P6 I wt hom wt wt wt 
P7 I wt hom wt wt wt 
P8 I wt het wt wt wt 
P9 I wt hom wt wt wt 
P10 I wt hom wt wt wt 
P11 I wt het wt wt het 
P12 I wt het wt wt wt 
P13 I wt hom wt wt wt 
P14 I wt hom wt wt wt 
P15 I wt hom wt wt wt 
P16 I wt hom wt wt wt 
P17 I wt hom wt wt wt 
P18 I wt hom wt wt wt 
P19 I wt wt wt wt wt 
P20 I wt hom wt wt wt 
P21 I wt hom wt wt wt 
P22 I wt wt wt wt wt 
P23 I wt het wt wt wt 
P24 I wt hom wt wt wt 
P25 I wt het wt wt wt 
P26 U wt hom wt wt wt 
P27 U wt het wt wt wt 
P28 U wt het wt wt wt 
P29 U wt het wt wt wt 
P30 U wt wt wt wt wt 
P31 U wt het wt wt wt 
P32 U wt hom wt wt wt 
P33 U wt hom wt wt wt 
P34 U wt hom wt wt wt 
P35 U wt hom wt het wt 
P36 U wt hom wt wt wt 
P37 U wt hom wt wt wt 
P38 U wt het wt wt wt 
P39 U wt het wt wt wt 
P40 U wt het wt wt wt 
P41 U wt het wt wt wt 
P42 R wt hom wt wt wt 
P43 R wt het wt wt wt 
P44 R wt het wt wt wt 
P45 R wt wt wt wt wt 
P46 R wt het wt wt wt 
P47 R wt het wt wt wt 
P48 R wt het wt wt wt 
P49 R wt het wt wt wt 
P50 R het hom wt wt wt 
P51 R wt hom wt wt wt 
P52 R wt het het wt wt 
60 
Ex 26 Ex 27 Ex 32 Ex 33 Ex 34 P AZA 
Response C2891T T3030C T3488C T3536C G3717A 
P53 R wt het wt wt wt 
P54 R wt hom wt wt wt 
P55 R wt hom wt wt wt 
P56 R wt hom wt wt wt 
P57 R wt hom wt wt wt 
P58 R wt het wt wt wt 
P59 R wt het wt wt wt 
P60 R wt hom wt wt wt 
P61 R wt hom wt wt wt 
P62 R wt hom wt wt wt 
P63 R wt het wt wt wt 
P64 R wt hom wt wt wt 
P65 R wt hom wt wt wt 
P66 R wt het wt wt wt 
P67 R wt hom wt wt wt 
P68 R wt het wt wt het 
P69 R wt hom wt wt wt 
P70 R wt wt wt wt wt 
P71 R wt hom wt wt wt 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Ex: exon;  
het: heterozygous; hom: homozygous; wt: wild type. 
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APPENDIX 3 
 
Summary of detected intronic XDH SNPs (Intron 1 – Intron 23)a 
 
Int 1 Int 4 Int 8 Int 17 Int 20 Int 23 P AZA 
Response C100+
27T 
A307-
33G 
T652-
21A 
G185
7-4A 
G2197+
42C 
G2197+
68A 
A2544+
35T 
P1 I wt wt wt wt wt wt hom 
P2 I het het wt wt het wt hom 
P3 I wt wt wt wt het het hom 
P4 I wt wt wt wt wt het het 
P5 I wt wt wt wt wt het het 
P6 I wt wt wt wt het het hom 
P7 I wt wt wt wt hom wt hom 
P8 I wt wt wt wt wt wt wt 
P9 I wt wt wt wt het het hom 
P10 I wt wt wt wt wt het hom 
P11 I het wt wt wt wt wt het 
P12 I wt wt wt wt wt wt het 
P13 I wt het wt wt wt hom hom 
P14 I wt wt wt wt het het hom 
P15 I wt wt wt wt hom wt hom 
P16 I wt wt wt wt het het hom 
P17 I wt het wt wt wt hom hom 
P18 I wt wt wt wt wt hom hom 
P19 I wt wt het wt wt wt hom 
P20 I wt het wt wt het wt het 
P21 I wt het wt wt het het hom 
P22 I het wt wt wt wt het hom 
P23 I wt wt wt wt wt het wt 
P24 I wt wt wt wt het het hom 
P25 I wt wt wt wt wt het het 
P26 U wt het wt wt het het wt 
P27 U wt wt wt wt wt wt het 
P28 U wt wt wt wt wt wt het 
P29 U wt wt wt wt wt het het 
P30 U wt het wt wt wt wt het 
P31 U het het wt wt wt wt hom 
P32 U wt wt wt wt wt hom hom 
P33 U wt wt wt wt het het hom 
P34 U wt wt wt wt wt hom hom 
P35 U wt wt wt wt wt het hom 
P36 U wt wt wt wt het wt hom 
P37 U wt het wt wt het het hom 
P38 U wt wt wt wt wt het het 
P39 U wt wt wt wt wt het het 
P40 U wt het wt wt wt het hom 
P41 U wt het wt het wt het hom 
P42 R wt wt wt wt wt hom hom 
P43 R wt wt wt wt wt wt het 
P44 R het wt wt wt het wt het 
P45 R wt wt wt wt wt wt wt 
P46 R wt wt wt wt het wt het 
P47 R wt wt wt wt het wt hom 
P48 R wt wt wt wt wt het het 
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Int 1 Int 4 Int 8 Int 17 Int 20 Int 23 P AZA 
Response C100+
27T 
A307-
33G 
T652-
21A 
G185
7-4A 
G2197+
42C 
G2197+
68A 
C100+2
7T 
P49 R wt wt wt wt wt het wt 
P50 R wt het wt wt hom wt hom 
P51 R wt het wt wt hom wt hom 
P52 R wt wt wt wt het wt het 
P53 R wt het wt wt wt wt wt 
P54 R wt wt wt wt het het hom 
P55 R wt wt wt wt wt hom hom 
P56 R wt het wt wt het wt hom 
P57 R wt wt wt wt wt het hom 
P58 R wt wt wt wt het wt het 
P59 R wt wt wt wt het wt het 
P60 R wt het wt wt wt het het 
P61 R wt wt wt wt wt het hom 
P62 R wt wt wt wt het het hom 
P63 R wt wt wt wt wt het het 
P64 R wt het wt wt wt wt het 
P65 R wt het wt wt hom wt het 
P66 R wt wt wt wt wt wt wt 
P67 R wt wt wt wt het het hom 
P68 R wt wt wt wt wt het het 
P69 R wt hom wt wt het wt het 
P70 R wt wt wt wt wt wt wt 
P71 R wt wt wt wt hom wt hom 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Int: intron; 
het: heterozygous; hom: homozygous; wt: wild type. 
 
Summary of detected intronic XDH SNPs (Intron 25 – 3’UTR)a 
 
Int 25 Int 27 Int 30 Int 34 3'UTR P AZA 
Response G2824
-35A 
C3052-
12G 
A3352-
30C 
C3774+
32G 
A4002+
518G 
A4002+
1477G 
C4002+
1516T 
G4002+
1555T 
P1 I wt hom wt wt het het het wt 
P2 I wt het wt het het wt het wt 
P3 I wt hom wt wt hom wt hom wt 
P4 I wt het wt wt hom wt hom wt 
P5 I wt het wt wt het het het het 
P6 I wt hom wt wt het het het het 
P7 I wt hom wt wt het wt het wt 
P8 I wt wt wt wt wt het wt het 
P9 I wt hom wt wt het wt het wt 
P10 I wt hom het wt het het het wt 
P11 I wt het wt wt wt hom wt hom 
P12 I wt het wt wt hom wt hom wt 
P13 I wt hom wt wt wt het het het 
P14 I wt hom wt wt hom wt hom wt 
P15 I wt hom wt wt wt wt wt wt 
P16 I wt hom wt wt het wt het wt 
P17 I wt hom wt wt het het het het 
P18 I wt hom wt wt hom wt hom wt 
P19 I wt wt wt wt wt het wt het 
P20 I wt hom wt wt hom wt hom wt 
P21 I wt hom wt wt hom wt hom wt 
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Int 25 Int 27 Int 30 Int 34 3'UTR P AZA 
Response G2824
-35A 
C3052-
12G 
A3352-
30C 
C3774+
32G 
A4002+
518G 
A4002+
1477G 
C4002+
1516T 
G4002+
1555T 
P22 I wt het wt wt hom wt hom wt 
P23 I wt het wt wt hom wt hom wt 
P24 I wt hom wt wt hom het het het 
P25 I wt wt wt wt het het het het 
P26 U wt hom wt wt het het het het 
P27 U wt het wt wt wt hom wt wt 
P28 U wt het wt wt wt het wt hom 
P29 U wt het wt wt het wt het wt 
P30 U wt wt wt wt wt het wt het 
P31 U wt het wt wt wt wt wt wt 
P32 U wt hom wt wt het het het het 
P33 U wt hom het wt wt het wt wt 
P34 U wt hom wt wt het het het het 
P35 U wt hom wt wt wt hom wt het 
P36 U wt hom het wt het het het wt 
P37 U wt hom wt wt het wt het wt 
P38 U wt het wt wt het het het het 
P39 U wt het wt wt hom wt hom wt 
P40 U wt het wt wt wt wt wt wt 
P41 U wt het wt het het wt het wt 
P42 R wt hom wt wt wt het wt het 
P43 R wt het wt wt het het wt hom 
P44 R wt het wt wt het het het het 
P45 R wt wt wt wt wt het wt het 
P46 R wt het wt wt wt wt wt wt 
P47 R wt het wt wt hom wt hom wt 
P48 R wt het hom wt het het het wt 
P49 R wt het wt wt hom wt hom wt 
P50 R wt hom wt wt het wt wt wt 
P51 R wt hom wt wt het het het het 
P52 R wt het wt wt het het het het 
P53 R wt het wt wt het wt het wt 
P54 R wt hom wt wt het wt het wt 
P55 R wt hom wt wt wt hom wt hom 
P56 R wt hom wt wt het het het wt 
P57 R wt hom wt wt wt het wt het 
P58 R wt het wt wt hom wt hom wt 
P59 R wt het wt wt wt hom wt hom 
P60 R wt hom het wt het het het wt 
P61 R wt hom hom wt wt hom wt het 
P62 R wt hom wt het het wt het wt 
P63 R wt het wt wt het het het het 
P64 R het hom het wt wt het wt wt 
P65 R het hom wt wt wt het wt wt 
P66 R wt hom wt wt wt wt wt wt 
P67 R wt hom wt wt het het het het 
P68 R wt het wt wt wt wt wt hom 
P69 R wt hom wt wt hom wt hom wt 
P70 R wt wt wt wt het wt wt wt 
P71 R wt hom wt wt hom wt hom wt 
a
 Only SNPs that were detected in at least one patient are shown; P: patient; Int: intron; 
het: heterozygous; hom: homozygous; wt: wild type.
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